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 The Rho family of GTPases comprises of approximately twenty family 
members, which regulate multiple cell activities including cellular migration, cell 
polarity, vesicle trafficking and a variety of enzymatic activities. Guanine nucleotide 
exchange factors (GEFs) activate Rho GTPases by removal of bound GDP and the 
subsequent of loading of GTP, which leads to downstream effector recognition. Two 
families of GEFs have been described: The classical Dbl-GEF family members share 
conserved DH-PH domains, where the DH domain harbors the GEF activity for the 
Dbl family members while the PH domain is thought to help localize the GEF protein 
to the plasma membrane. In contrast to Dbl-GEFs, the more recently described 
Dock180 GEF-family members do not share primary sequence homology with DH-PH 
domains, although they exhibit robust nucleotide exchange activity for Rho GTPases. 
Here we describe the biochemical characterization of the conserved limit DHR-2 
domain of Dock180 and its activation of the Rac GTPase. We delineate a limit 
functional sub-domain of DHR-2 which is composed of approximately 300 residues in 
the C-terminal portion of DHR-2 (referred to below as DHR-2c). Our data show this 
region is both necessary and sufficient for robust GEF activity as the DHR-2 domain 
specifically activated Rac both in vitro and in vivo. Scanning mutagenesis of Rac also 
revealed that DHR-2c binds to Rac in a manner distinct from the classical Dbl-family 
Rac-GEFs. Specifically, both alanine 27 and tryptophan 56 of Rac are demonstrated to 
provide a bipartite recognition site for DHR-2c GEF-specific recognition, whereas, for 
  
Dbl-family GEFs, tryptophan 56 of Rac is the primary determinant of GTPase 
specificity. We also identified the corresponding residue (methionine 1524) on 
Dock180 to specifically recognize tryptophan 56 of Rac. These results define the core 
residues for Dock180’s guanine nucleotide exchange activity while highlighting 
recognition sites that underline GTPase specificity for Dock180-family members.  
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CHAPTER 1 
INTRODUCTION 
1.1 Rho GTPases and their regulators 
 1.1.1 GTPase cycle  
 The Ras GTPase superfamily comprises a large number of proteins, which 
participate in a wide range of signaling pathways in cells. They are key regulators of a 
number of biological processes including cell movement, cell differentiation, 
programmed cell death, vesicle transport and the regulation of the actin cytoskeleton 
(1, 2). Based on their structural and functional distinctions, this superfamily can be 
further divided into five families referred to as the Ras, Rab, Ran, Arf and Rho 
subfamilies (3). As outlined in Figure 1.1, Ras family members are generally thought 
to control cell proliferation(4) while Rab GTPases control vesicle trafficking (5). Rho 
GTPases direct cell mobility and cytoskeletal reorganization and stimulate the 
activation of specific nuclear kinases (6) while Ran GTPases regulate nuclear import 
and export(7), and Arf GTPases influence intracellular trafficking and microtubule 
organization (8). However, the specific functions of Ras superfamily proteins are not 
limited to the above mentioned processes but in fact can impact a broad range of 
cellular events. Members of different families may also cooperate in specific signaling 
pathways (9). 
 The Rho (for Ras-homologous) family of GTPases includes of approximate 
twenty members (10). The best studied members are Rho, Rac and Cdc42. Like all 
other GTP-binding proteins, Rho family proteins exist in two different states, a GDP-
bound inactive state and a GTP-bound active state. The GTP-binding/GTP-
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Figure 1.1 Schematic representation of the five sub-families of the Ras superfamily 
and their cellular functions  
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hydrolytic cycles of Rho proteins are tightly regulated as their intrinsicrates of GDP-
GTP exchange and GTP hydrolysis are very low and not sufficient to quickly respond 
to cellular signals. With the help from two families of regulatory proteins, GEFs and 
GAPs, as summarized in Figure 1.2, Rho GTPases can be turned on and off at much 
higher rates. GEFs (for guanine nucleotide exchange factors) stimulate the exchange 
of GDP for GTP on Rho GTPases (11) while GAPs ( for GTPase-activating proteins) 
accelerate the hydrolysis of GTP to GDP and thereby shutdown the function of the 
GTPases (12). 
  
 1.1.2 Signaling from receptors to Rho GTPases to biological effectors 
 In 1992, the first cellular response to Rho protein activation was discovered 
(13). Since then, a number of cellular signaling activities and biological responses 
involving Rho GTPases have been identified. A good deal of progress has also been 
made regarding the identification of extracellular stimuli and cell surface receptors 
that promote the activation of Rho proteins. For example, Cdc42 has been shown to be 
activated by several types of extracellular signals. One in particular is EGF, which 
binds to the EGF receptor tyrosine kinase. The EGF-dependent activation of Cdc42 is 
mediated through the activation of the Src tyrosine kinase and various Cdc42 GEFs 
including Vav2 and Cool-1 (14, 15). RhoA can be activated by LPA, which binds to a 
G protein-coupled receptor and activates the large G protein G• 12/13. Activated G• 12/13 
in turn binds to the RGS (for regulation of G protein-signaling) domain of a Rho-GEF 
(p115-RhoGEF) which activates RhoA (16).  
 Activated Rho family GTPases bind to a wide variety of downstream targets 
and effector proteins. Among the original functions discovered for the Rho-family
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Figure 1.2 Signaling from receptors to Rho GTPases to effectors. The GTPase 
cycle is regulated by GEFs, GAPs and GDIs. 
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GTPases is the regulation of actin polymerization. Specifically, Rho proteins 
contribute to contractility and actin stress fiber formation. Rac stimulates the 
formation of lamellipodia while Cdc42 promotes the formation of filopodia (13). 
There are more than 60 known target and effector proteins that bind to activated 
(GTP-bound) Cdc42, Rho and Rac. These target proteins generally do not contain 
similar recognizable motifs. However, most appear to contain a conserved GTPase-
binding domain (GBD) which can recognize the GTP-bound form of the Rho GTPases. 
In some cases, activated Cdc42 regulates the function of effector proteins, i.e. PAK 
and WASP, by altering the structure of the GBD and the release of an auto-inhibitory 
(17).  
 Signaling pathways induced by different Rho proteins show a significant 
degree of crosstalk, as different Rho proteins may activate or inhibit each other either 
directly or indirectly. For example, Ridley and Hall showed (13) that Ras- induced 
membrane ruffling was due to the Ras-promoted activation of Rac and then RhoA. 
Cdc42 was later found to be in the same pathway in some cells. The Rho GTPases can 
also affect other Ras superfamily members either by stimulating a GAP to suppress 
their activity or by simulating a GEF to activate their signaling function.  
  
 1.1.3 Regulating Rho GTPases 
 Rho GTPases are central participants in cellular signaling pathways. They 
influence a wide range of cellular and biological responses. It often becomes important 
that these GTPases are rapidly activated when it is necessary to trigger a cellular 
response, and then quickly deactivated when the response needs to be terminated. To 
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achieve this, three main families of regulatory protein are involved, i.e., GEFs, GAPs 
and GDIs.  
 To activate Rho GTPases, the rate limiting step is the exchange of GDP to 
GTP. The function of GEFs is to accelerate the nucleotide exchange reaction. The 
GEF proteins bind to the GTPases and modify their nucleotide-binding sites, thus 
reducing the nucleotide- binding affinity. Because of the high concentration of GTP 
(i.e. 10 fold) in cells, following GEF-catalyzed GDP dissociation, GTP will bind to the 
GTPase and catalyze its dissociation from the GEF, thus enabling it to bind to its 
biological effectors (11, 18) 
 The GAP family comprises a group of proteins which help accelerate the rates 
at which GTPases hydrolyze GTP to GDP. Most of the GAPs for the Rho GTPases 
share a conserved arginine residue called an ‘arginine finger’. It ‘points’ into the 
active site of Rho GTPases thereby stabilizing the transition state for GTP hydrolysis. 
This interaction increases the rate of GTP hydrolysis by more than one-thousand-fold 
(19, 20). 
 Compared to GEFs and GAPs, the Rho GDI family is much smaller. It 
contains only three members and a few other proteins which have been suggested to 
have GDI activity. The GDIs inhibit GDP-dissociation and nucleotide exchange, as 
well as blocks GTP hydrolysis (21, 22). However, the main cellular function of the 
GDI is to help maintain Cdc42 and other Rho proteins in a soluble state until the 
appropriate signals are received, enabling the GTPases to bind to effector proteins at 
the membrane (23, 24). 
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1.2 Dbl-GEFs and Dock180 GEF family 
 1.2.1 Classic GEF family – Dbl Family 
 Dbl, which was isolated in 1985 (25), was the  first Rho GEF to be identified 
(26). It contains a region which showed significant similarity to Cdc24 (27), a protein 
that was suspected to be an upstream activator of Cdc42 in yeast. This region was 
named the DH-domain (Dbl-homology domain), and is essential for the GEF activity 
of Dbl(28). Since that initial discovery, a number of Rho GEFs have been isolated. 
There are now known to be 46 Rho GEFs in humans and a number of family members 
in other species. These proteins comprise what is called the Dbl-GEF family. All of 
the family members share two conserved domains, a 200-amino-acid DH domain 
followed by a 100 amino-acid PH-domain (Pleckstrin-homology domain). The DH 
domain is mainly responsible for the GEF catalytic activity. The PH domain, adjacent 
and C-terminal to the DH domain, may have several different functions. A primary 
function is the binding of  phosphoinositide lipids as well as other proteins, which in 
turn can either directly affect the catalytic activity of the DH domain (29) or help 
target the GEF to the appropriate location in cells (30). In addition to these two 
conserved domains, Dbl GEFs may contain other regulatory and binding domains. 
These domains help to regulate the activity of GEFs or couple the GEFs to upstream 
receptors or signaling molecules. Some of the GEFs are found to be highly specific for 
one GTPase, such as Tiam1 for Rac, Intersectin for Cdc42, and p115RhoGEF for Rho. 
Others may activate several GTPases, i.e., Vav activates Cdc42, Rac and Rho, and Dbl 
activates Rho and Cdc42 (31). The specificity is determined by the structure of the 
GEFs and GTPases. However, the specific regions on the GEF critical for Rho 
GTPase recognition still remain to be established.  
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 1.2.2 Regulation of Dbl-GEFs 
 GEFs are key regulatory proteins as they are directly responsible for activating 
small GTPases. Mutations in GEFs that cause them to be de-regulated or excessively 
active give rise to serious diseases including cancer and developmental disorders.  
 In normal cells, GEF proteins are tightly regulated through a number of 
mechanisms. One of the most common regulatory mechanisms is auto-inhibition. Vav 
provides one of the best-understood examples of auto-inhibition. The N-terminal 
region of Vav bends over and binds to the active site of the DH domain thus blocking 
the access of Rho-GTPases (32). Removal of the N-terminal sequence leads to 
constitutive activation. The auto-inhibition can be released in certain circumstances. 
For example, phosphorylation of tyrosine residue 174 of Vav at the N-terminal region 
releases it from binding to the DH domain (32). 
 The activity of GEFs can also be regulated by direct protein-protein 
interactions. Cool-2 shows different GEF capability depending upon whether it is 
monomer or dimer. When Cool-2 is a dimer, it acts as a Rac-specific GEF, whereas 
when Cool-2 is a monomer, it can serve as a GEF for either Cdc42 or Rac. However, 
monomeric Cool-2 fails to show any GEF activity unless the SH-3 domain interacts 
with the Cdc42/Rac –effector protein PAK. PAK-bound monomeric Cool-2 exhibits 
GEF activity toward both Rac and Cdc42 (33). More recently, it was shown that the 
Rac-GEF activity of dimeric Cool-2 is activated by GTP-bound Cdc42 (34).  
 The GEFs can also be regulated by localization. Because the activation of 
GTPases by GEFs normally occurs at the plasma membrane, the recruitment of GEFs 
to the membrane is often an essential step for signaling in cells. The PH domain of 
GEFs is normally the domain responsible for the localization of the Dbl-GEFs, in 
many cases as an outcome of its binding to phosphoinositides (30). 
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 1.2.3 Dock180 family: Newly discovered Rho GEFs  
 In 1996, Matsuda’s group discovered a protein with a relative molecular 
weight of 180 kDa, which interacts with the small adapter protein Crk (35, 36). 
Subsequent studies showed that Dock180 and its homologues in Drosophila 
(Myoblast City) (37) and C.elegans (Ced-5) (38) are involved in a number of 
biological process including actin cytoskeleton reorganization, phagocytosis of dead 
cells, cell migration and myoblast fusion. Dock180 was shown to be an upstream 
regulator of Rac, and biochemical analysis confirmed that it functioned as a Rac-GEF. 
However, Dock180 does not have tandem DH and PH domains and it shares very low 
sequence similarity with Dbl-GEFs (39, 40).   
 Further examination of gene data bases demonstrated the existence of several 
related proteins in mammals. Together with Dock180, these proteins form a new GEF 
family called the Dock180 superfamily (39). At least eleven mammalian members and 
several more in other species, such as worms, fruit flies and yeast, have been 
discovered. The eleven members have been designated Dock1 (Dock180) to Dock11 
for convenience.  
 Most of the Dock180 family members have been cloned and shown to exhibit 
GEF activity toward Rho family GTPases. The eleven members have been further 
divided into four subfamilies named Dock A to Dock D. Within the whole superfamily, 
there are two domains conserved, which are named the DHR-1 (Dock180 Homology 
Region-1) domain and the DHR-2 domain. Outside these two domains, different 
subfamily members have several other domains and the similarity of these regions 
among different subfamilies is quite low (40).  
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 1.2.4 Functions of Dock180 family members 
 Recently, several groups have been studying the functions of Dock180 and 
other family members and some characterizations have already been reported. 
However, in many cases, the mode of action of Dock180 family members is still far 
from fully understood, especially when compared to what is known about Dbl-GEFs.  
 The Dock A subfamily includes Dock180 (Dock1), Dock2 and Dock5, with all 
of the family members being Rac-specific GEFs. Each contains an SH-3 domain at the 
N-terminal, in addition to DHR-1 and DHR-2 domains. Dock180 has an extra proline-
rich domain at its C-terminal end. The SH-3 domain interacts with a protein called 
Elmo which is essential for the activation for Dock180 and Dock2. The proline-rich 
domain binds to Crk II, which is a well-known signaling adapter protein (41). The 
detailed mechanism underlying the GEF activity of Dock180 will be elaborated upon 
later.  
 Dock2 was found to be important for lymphocyte migration. Chemotaxis is 
crucial in the immune response. In order to undergo chemotaxis, cells need to establish 
a polarized morphology, which includes the formation of a leading lamellipodium and 
a rear compartment. The formation of lamellipodium requires the activation of Rac, 
which can be promoted by Dock2 during lymphocyte migration. Deletion of Dock2 in 
mouse cells abolished lymphocyte migration in response to lymphoid chemokines (42). 
However, how Dock2 responds to chemokine receptors is still not understood. Dock5 
has been reported to be functional in the establishment of lens integrity but the 
mechanism is very poorly understood. 
 The Dock B subfamily includes Dock3 and Dock4. Both are also specific 
GEFs for Rac similar to the Dock A members. However, the similarity of the DHR-2 
domain between the two subfamilies is only approximately 17%. Dock3, also known 
as MOCA (the Modifier of Cell Adhesion), was originally identified as a presenilin-
13 
 
binding protein. It has an SH-3 domain and two proline-rich domains. It is localized 
specifically in neurons and has been demonstrated to bind Rac and induce GTP 
loading onto Rac, which leads to the activation of JNK and cell morphology changes 
(43). Dock4 was originally discovered as a gene missing in tumor progression. 
Subsequent research demonstrated that Dock4 has tumor suppressor properties. It is 
regulated by the small GTPase RhoG and forms a complex with Elmo to activate Rac, 
which then promotes cell migration. It has also been shown to regulate dendritic 
growth and branching through activation of Rac in neurons (44-46). 
 The Dock C subfamily is comprised of three members, Dock6, Dock7 and 
Dock8. These GEFs are different from other Dock180 family members because they 
are potential GEFs for both Cdc42 and Rac. Dock6 is involved in neurite outgrowth 
and a Dock8 mutant was found in lung cancer cells (47, 48). Both of these proteins are 
important regulators for lamellipodia formation. Dock7 is the best known member of 
this subfamily. Recent work has shown that Dock7 is directly activated by the 
neuregulin/heregulin receptor Erb2. Erb2 binds to Dock7 and phosphorylates Tyr-
1118 of Dock7. Activated Dock7 then induces the migration of Schwann cells(49). 
Other studies have shown that Dock7 contributes to the polarization of neurons and to 
the regulation of axon formation (50, 51). 
 Dock9 (Zizimin1), Dock10 (Zizimin3) and Dock11 (Zizimin2) comprise the 
Dock D (Zizimin) subfamily. Each of these proteins acts as specific GEFs for Cdc42 
(52). They share similar primary sequence and function in cells. However, their tissue 
distribution is distinct. For example, Zizimin1 is enriched in non-hematopoietic tissues, 
while Zizimin2 is expressed mainly in lymphocytes (53). Zizimin2 was originally 
discovered in our laboratory through its ability to bind to the activated form of Cdc42 
(also called ACG – Activated Cdc42-associated GEF). ACG can bind to both the 
GDP- and GTP-bound forms of Cdc42 which is quite different from other Dock180 
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GEFs. It binds to activated Cdc42 in a manner that enables the positive feedback 
stimulation of GDP-GTP exchange on Cdc42, similar to the activation of Cool-2 by 
GTP-bound Cdc42 (34, 54).  
 
1.3 Function of Dock180 in phagocytosis 
 1.3.1 Recognizing the apoptotic signals of dying cells 
 Dock180 is involved in multiple, fundamentally important biological processes 
which include: actin cytoskeletal changes, cell migration and polarity, and the 
phagocytosis of apoptotic cells in mammals. Among these various processes, the role 
of Dock180 in phagocytosis is probably the best understood.  
 Apoptosis is a form of programmed cell death in multi-cellular organisms. 
Apoptosis can occur during cell damage, viral infection or as an outcome of disease. It 
also occurs during negative selection in development or the homeostatic turnover of 
cells in various tissues. Proper removal of these cells can prevent the leakage of cell 
contents, secondary necrosis and inflammation. Engulfment also functions in tissue 
remodeling and immune response regulation. The engulfment of apoptotic cells is 
mainly executed by those ‘scavenger’ cells, called phagocytes, including macrophages 
and immature dendritic cells.  
 Programmed cell death is a very complex process involving multiple signal 
transduction pathways. It is normally composed of two distinct processes: cell suicide 
and the removal of dead cells (55). To remove apoptotic cells, the dying cells must 
first be recognized by phagocytes. These signals include the exposure of 
phosphatidylserine (PtdSer), which is normally located at the inner-membrane of cells 
(56), changes in glycoproteins and lipids on the surface membrane (57), or the binding 
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of thrombospondin to the apoptotic-cell surface (58). There are also other poorly-
defined molecules which function as the surface signals or ‘bridge’ signals. To 
recognize these signals, phagocytes express different types of receptors. For example, 
PtdSer needs to be recognized directly or indirectly by phagocyte receptors. PtdSer 
can directly bind to receptors such as BAI1 (59), whereas it can indirectly bind to 
bridging molecules such as calreticulin and C1q and then be further recognized by 
additional receptors (60).   
 
               1.3.2 Regulation of actin cytoskeletal remodeling during engulfment in 
C.elegans  
 After phagocytes receive the signals sent by apoptotic cell, the signals are 
transferred downstream, causing the cytoskeleton of the phagocyte to reform and 
surround the apoptotic cell through a complex sequence of events. Dock180-mediated 
Rac activation in phagocytosis is conserved from C.elegans, to Drosophila and 
ultimately to mammals. To understand the mechanism of phagocytosis, researchers 
have been focusing on the engulfment process in C.elegans, a simple model organism, 
and trying to identify genes involved in how these proteins transfer the necessary 
signals for engulfment. These efforts have helped to establish a signing network 
comprised of receptors, activators, inhibitors and effectors. Understanding the network 
operating in C.elegans that is responsible for engulfment should help to identify 
similar genes in mammals that are involved in similar functions. 
 In C.elegans, Ced-10 (Rac1 in human) is a key regulator of the actin 
cytoskeleton during the engulfment of apoptotic cells (61). It appears to sit at the 
crossroad for different signaling pathways involved in apoptosis. Until now, two 
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independent but partially redundant pathways have been identified that function 
upstream of Ced-10 (60). The first pathway, which is not well studied, consists of 
Ced1, Ced6 and Ced7. Ced1 and Ced6 function as a receptor complex to recognize 
signals sent by dying cells (62). Their mammalian orthologues are the transmembrane 
receptor LRP1/MEGF-10 and the adaptor protein GULP. In mammals, LRP1 also 
interacts with GULP to play a role in phagocytosis. They bind to calreticulin and 
indirectly interact with PtdSer (63). Ced-7 is a unique gene product which is thought 
to function as a transport protein in both phagocytic and apoptotic cells. However, 
what it transports and how Ced-7 cooperates with Ced1 and Ced6 remains to be 
determined. Its orthologue in mammals is ABCA (ATPase Binding Cassette A), which 
also participates in cholesterol transport across the plasma membrane. The proteins 
working downstream from Ced1-Ced6-Ced7 and finally activating Ced10 (Rac1) are 
still not known. However, mutants of Ced1 or Ced6 severely impair phagocytosis, 
which demonstrates that this pathway is upstream of Rac and critical for engulfment. 
 The second pathway that functions upstream of Ced-10 includes Ced-2, Ced-5 
and Ced-12. Ced-5 is similar to the human protein Dock180 and the Drosophila 
melanogaster protein Myoblast City (MBC) (37, 38, 64). It was found to regulate Ced-
10 (Rac) (Figure 1.3). Ced-5 mutants are defective in the engulfment of cell corpses. 
Ced-2 (CrkII in human) interacts directly with Ced-5, which may interact with the 
receptor and co-localize the Ced-5/Ced-10 complex to the plasma membrane. Ced-12 
(Elmo) lacks catalytic activity, but is necessary for the activation of Ced-5. The Ced-
2/Ced5/Ced-12 complex is required for Ced-10 activation. However, which receptor is 
involved in this pathway is still unclear.  
 In mammalian cells, Rac is linked to actin cytoskeletal reorganization in many 
types of cellular functions. When Rac is in its active state, it binds to a number of 
downstream targets which regulate a variety of cellular responses including cell  
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Figure 1.3 Conserved Rac activation pathway involved with Elmo/Dock180 
in both mammals and C.elegans  
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migration, lamellipodia formation, MAP kinase activation and cell-cycle progression. 
The mechanism by which Rac is activated is conserved in a number of species, i.e. 
worms, flies and mammals, and is crucial for apoptotic cell clearance (38). Within the 
Dock180 superfamily, Dock180 is the best known GEF for Rac. In vivo experiments 
have already demonstrated that Dock180 is co-localized with Rac in the membrane 
ruffles of phagocytes. Deletion of the gene encoding Dock180 severely impairs the 
uptake of apoptotic cells by phagocytes.  
 
1.4 Regulation of Dock180-Rac complex 
 1.4.1 The bipartite GEF model with Dock180 and Elmo 
 It has already been demonstrated that the DHR-2 domain of Dock180 is 
sufficient to activate Rac both in vitro and in vivo (39, 40). The DHR-2 domain is 
continuously active in cells and can replace the function of Dock180 in mediating cell 
elongation and migration. However, in cells, full-length Dock180 is in an inactive 
state until upstream signals activate its Rac-GEF activity. In the absence of such 
regulation, it might be expected that Dock180 would give rise to an excessive 
activation of Rac, which in turn could have important consequences with regard to 
cancer and other disorders. Thus, an important question concerns how Dock180 is 
regulated in cells. Several mechanisms have been recently uncovered. 
 Elmo was the first protein that was found to affect Dock180 function and Rac 
activation. Elmo does not have any enzymatic activity and can not trigger Rac 
activation in cells in the absence of Dock180 (64). However, the co-expression of 
Elmo and Dock180 in cells significantly increases GTP-loading onto Rac (40). There 
are three different isoforms of Elmo, designated as Elmo1, Elmo2 and Elmo3. Each 
can form a complex with Dock180 and several other members of the Dock180 
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superfamily. The Elmo proteins are comprised of approximately 700 amino acids. 
They appear to function as scaffold proteins, containing a single PH domain at the C-
terminal end followed by a proline-rich motif. In addition, several Armadillo (ARM) 
repeats are present at the N-terminus which may be involved in binding to the small 
GTPase RhoG (see below) (65). The interaction of RhoG with Elmo may help Elmo to 
release the auto-inhibition of Dock180. 
 The auto-inhibition of Dock180 is thought to occur as an outcome of an 
interaction between its SH-3 domain, located near the N-terminus, and the DHR-2 
domain, although there is no obvious proline-rich motif within DHR-2 (66). This 
interaction blocks the binding domain for Rac and thereby prevents Rac activation. 
Deletion of the SH-3 domain significantly enhances Rac activation in cells by 
Dock180. Thus, the function of Elmo is to release the auto-inhibition by binding to the 
SH-3 domain of Dock180. Single residue mutations at the SH-3 domain of Dock180, 
which abolishes its ability to bind to Elmo, significantly decrease Rac activation by 
Dock180 in cells. These results have led to the suggestion that Elmo and Dock180 act 
as a bipartite GEF for Rac activation (67).  
 Several other functions of Elmo were also discovered recently. First, Elmo 
may help stabilize the transition state for the activation of Rac by Dock180. This was 
suggested by the finding that in the absence of Rac, Elmo can not bind to a Dock180 
mutant lacking the SH3 domain, but it can form a trimeric complex with this Dock180 
mutant and Rac (66). In addition, the PH domain of Elmo functions to co-localize the 
Dock180-Elmo complex to the plasma membrane where Rac can become activated 
and then bind to its effector proteins (68). There is also evidence that over-expression 
of Elmo prevents the ubiquitination of Dock180. Knock-downs of Elmo by siRNAs 
cause the rapid degradation of endogenous Dock180 (69). Interestingly, Crk, which is 
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another binding partner for Dock180, increases Dock180 ubiquitination when over-
expressed.  
  
 1.4.2 The Phosphatidylserine Receptor and RhoG activate the Elmo-
Dock180 complex 
 In C.elegans, both Ced-5 and Ced-12 have been shown to interact directly with 
the PtdSer receptor. Recently, in mammalian cells, one of the PtdSer receptors called 
BAI1 was found to form a ternary complex with Elmo and Dock180 (59). BAI1 is a 
seven transmembrane protein belonging to the family of G-protein-coupled receptors 
whose extracellular domain binds to phosphatidyserine on apoptotic cells. Inhibition 
of the expression of BAI1 weakens the engulfment of apoptotic targets. The function 
of this receptor is not well studied; however, this is the only receptor which has been 
discovered to directly interact with the Elmo-Dock180 complex.  
 Other proteins have also been found to be important for the Dock180-mediated 
activation of Rac through Elmo. As alluded to above, one such protein is RhoG. RhoG 
recruits the Elmo-Dock180 complex to the plasma membrane (65). Also in C.elegans, 
Mig-2, the homologue of RhoG, and its GEF UNC-73, function as upstream regulators 
of Ced-5-mediated activation of Ced-10 (70). However, the identity of the receptors 
that activate RhoG and how the signal is transferred from the receptors to RhoG 
remains to be understood. 
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 1.4.3 A parallel signaling pathway to activate Dock180 through Crk II 
 Although Dock180 was originally discovered as a binding protein for Crk II, 
there is no definitive evidence that Crk II is essential for the Elmo-Dock180-mediated 
activation of Rac in cells. The proline-rich-domain truncated mutation of Dock180, 
which no longer binds to Crk II, can still activate Rac in vivo with the help of Elmo. 
However, recent studies suggest that there is another signaling pathway through Crk II 
to Dock180, which is possibly parallel to the Elmo-Dock180 pathway (Figure 1.3). It 
has been reported that integrins, which respond to fibronectin, stimulate p130Cas and 
paxillin by phosphorylation. Phosphorylated p130Cas binds to Crk II and later forms a 
complex with Dock180 (41, 71). While this pathway offers some intriguing 
possibilities regarding the cellular regulation of Dock180, its true cellular and 
biological significance is still not known. 
  1.4.4 The importance of The DHR-2 domain 
 To understand the mechanism of Rac activation by Dock180, the DHR-2 
domain needs to be investigated in detail. Thus far, not much work has been done in 
the way of biochemical characterization of this domain. The DHR-2 domain of 
Dock180 as well as other family members is difficult to express in E.coli, and 
consequently, recombinant preparations of high purity and quality protein have been 
extremely difficult to obtain. However, in our laboratory, we have successfully cloned 
a functional domain of DHR-2 and expressed this domain in E.coli. This has opened 
the way to a good deal of biochemical studies and mutagenesis analysis. In the next 
two chapters, I will focus on the discovery of a new limit functional region for DHR-2, 
my efforts to obtain its structure, and biochemical studies comparing the mechanism 
used DHR-2 versus the DH domain of Dbl-GEFs to activate Rac. 
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CHATPER 2 
A NEW FUNCTIONAL LIMIT DOMAIN OF DOCK180  
2.1 Introduction 
 Dock180 was originally identified as an unconventional Rac-GEF protein 
because it lacked the tandem DH-PH domain, which is a hallmark of all Dbl-GEF 
family members. A family of GEFs for Rac and Cdc42 was subsequently discovered 
for which the founding member is Dock180. This family of GEFs includes eleven 
members in mammalian cells and a number of orthologues in yeast, worms, flies and 
other species. These proteins share two conserved domains, designated as DHR-1 
(Dock180 homology region-1) and DHR-2 (2). The DHR-2 domain comprises 
approximately 500 amino acids and responsible for the GEF activity of Dock180. As 
discussed in the previous chapter, Dock180 family can be further divided into four 
sub-families. As shown in Figure 2.1, the sequence identity for the DHR-2 domain 
among members of a given subfamily is high (i.e., the identity of DHR-2 between 
Dock180 and Dock2 is more than 70%), whereas the identity between members of 
different sub-families is quite low (i.e. the identity of DHR-2 between Dock180 (Dock 
A subfamily) and Dock7 (Dock C subfamily) is less than 15%). However, based on 
secondary structural predictions, the secondary structure of the DHR-2 domain of 
Dock180 and Dock7 is similar as shown in Figure 2.2, suggesting that they share a 
common tertiary structure and activation mechanism for their GEF activity. 
 Several groups have already successfully expressed the DHR-2 domain of 
Dock180 and other family members in vitro and in vivo. It has been shown that the 
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Figure 2.1 Primary sequence alignments of the DHR-2 domains from the 
Dock180 superfamily. The amino acids used from the respective sequences are as 
follows: Dock7 (1257-1894), Dock2 (1092-1670), and Dock180 (1088-1672). 
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Figure 2.2 Secondary structural predictions for the DHR-2 domain of Dock180 
and Dock7 using J-pred. 
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DHR-2 domain binds to and activates Rac in vitro and is also necessary and sufficient 
for the Dock180-mediated activation of Rac in vivo, while other domains (the SH-3, 
DHR-1, and proline-rich domains) of Dock180 do not appear to directly contribute to 
Rac activation. Experiments performed in vitro have also shown that the DHR-2 
domain exhibits significantly higher GEF activity than the full-length Dock180 which 
is subject to auto-inhibition (3). 
 Although the DHR-2 domain of Dock180 has been expressed in E.coli by 
several groups, it has been difficult to isolate the DHR-2 domains and typically only 
very low yields of protein have been obtained (100 µg level from 1 L culture). Efforts 
have been made to identify possible sub-domains of DHR-2 by secondary structure 
analysis. It was claimed that DHR-2 might contain a ‘DH’ domain (i.e. within amino 
acids 1111 to 1335) and a ‘PH’ domain (amino acids1395-1515) (4). However, none 
of these sub-domains have shown GEF activity toward Rac. Based on these results, it 
has been concluded that the entire DHR-2 domain (including amino acids 1111 to 
1657) is necessary for Rac activation.  
 However, when we began to examine and characterize the DHR-2 domain, we 
obtained some results that were not consistent with previous published work. In 
particular, we identified a more limit sub-domain of DHR-2 which is well expressed in 
E.coli. Either in vitro or in vivo, this sub-domain can fully replace the GEF activity of 
Dock180. And it is much stable than the full-length DHR-2c and shows specific GEF 
activity towards Rac. Our fluorescence data demonstrated that this sub-domain 
showed relatively high GEF activity comparing to classical Dbl-GEF proteins.  
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2.2 Methods 
 Plasmids. The Dock180 plasmid was a gift from Michiyuki Matsyda. To 
obtain the clone of the original DHR-2 domain (amino acids 1178-1657), the 
polymerase chain reaction (PCR) was performed using the Dock180 plasmid as 
template DNA and primers 5’ –GCGGATCCATGGAAAGGC TTTTGGAT -3’ and 
5’-CGGAATTCTCACGATGAG AGGGAAGAGA-3’. The PCR product was cloned 
into the pET28a plasmid using BamH I and EcoR I restriction sites. The DHR-2n sub-
domain (1178-1334) and the DHR-2c sub-domain (1135-1657) constructs were 
generated by PCR using DHR-2 as the template and cloned into both pET28a and 
pKH-3 plasmids.  
 Protein Expression and Purification. Single colonies of E.coli BL21 (DE3) 
containing target plasmids were inoculated in 10 ml of LB media with 50 µg/ml 
kanamysin or carbenicillin (RPI) and cultured overnight at 37°C.  These small cultures 
were subsequently used to inoculate 1 L LB media with 50 µg/ml kanamysin/ 
carbenicillin in a shaking incubator at 37°C. The large-scale cultures were incubated 
to a density of ODR600R=0.6 and induced by IPTG (RPI) (final concentration = 200 µM) 
at room temperature overnight. Bacteria were harvested by centrifugation at 5000 rpm 
for 10 minutes and the pellet was re-suspended in lysis buffer (20 mM Tris-HCl PH 
8.0, 5 mM MgClR2R, 500 mM NaCl) with 10 µg/ml leupeptin and 10 µg/ml aprotinin.  
 For DHR-2, DHR-2c and DHR-2n, the suspensions were sonicated and the 
lysates were cleared by centrifugation at 20000 rpm for 30 minutes. The supernatants 
were collected and incubated with nickel chelate beads (Amersham) for 30 minutes on 
ice. The beads were washed with lysis buffer containing 40 mM imidazole until there 
was no detectable protein in the wash buffer. The proteins were eluted with lysis 
39 
 
buffer containing 200 mM imidazole, concentrated to 200 µM, and stored at -80°C for 
further use. 
 Rac and Cdc42 were expressed using similar procedures as described above 
and the supernatants were collected and applied to a glutathione-sepharose column. 
Unbound proteins were washed off by lysis buffer and target proteins were eluted 
using the same buffer with 10 mM glutathione. The eluted proteins were applied to a 
P-10 desalting column to remove glutathione and concentrated to 300 µM. Mant-
GDP-Rac and mant-GDP-Cdc42 were prepared by mixing Rac with a 10-fold excess 
of mant-GDP in lysis buffer with 10 mM EDTA for 10 minutes. Excess MgClR2R was 
added to saturate EDTA. The mixture was applied to a P-10 desalting column 
equilibrated in lysis buffer in order to remove unbound mant-GDP. 
 In order to obtain highly purified protein for crystallization, DHR-2c, bound to 
nickel beads, was incubated with thrombin (Haemotologic Tech) (1 unit for 3 mg 
target protein) to digest the His-tag overnight at 4°C. The flow-through was collected, 
concentrated and applied to a HiTrap Q HP column using AKTA FPLC (GE). DHR-
2c does not bind to the Q column and so the flow-through was collected and 
concentrated to a volume of 5 ml. The concentrated protein was then applied to a G-75 
gel-filtration column which was pre-equilibrated with crystallization buffer (Tris-HCl 
20 mM pH 8.0, 100 mM NaCl). The fractions containing DHR-2c were examined by 
SDS-PAGE gel. The highly purified DHR-2c was concentrated to 10 mg/ml for 
crystallization screens. 
 High quality His-Tag Rac was purified in a similar manner except that MgClR2 
R(5 mM) was present in solution throughout the purification. Purified Rac and DHR-2c 
were mixed at the molar ration 2:1 in crystallization buffer with 10 mM EDTA for 30 
minutes at 4°C. The mixture of Rac and DHR-2c was then applied to a G-200 gel-
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filtration column. The protein complex was identified by SDS-PAGE and concentrated 
to 10 mg/ml for crystallization screens. 
   In vitro GEF Assay. All fluorescence measurements were performed using a 
Varian Ecilpse Fluorescence Spectrophotometer. Samples were stirred continuously 
and thermostated at 25°C in HMA buffer (20 mM HEPES pH 8.0, 5 mM MgClR2R, 1 
mM NaNR3R). In vitro GEF assays using mant-GDP as a probe to monitor fluorescent 
changes accompanying nucleotide exchange were performed on recombinant GTPases. 
Mant-GDP was added to HMA buffer to a final concentration of 1 µM. Different 
concentration of Rho GTPases (Rac, Cdc42) and their mutants were added together 
with various concentrations of GEF proteins (DHR-2, DHR-2c). The Mant-GDP 
fluorescence changes were monitored using an excitation wavelength of 340 nm and 
an emission wavelength of 440 nm at 25°C. Each measurement was repeated at least 
three times. When measuring the turn-over rate of the GEF proteins, Rac were 
preloaded with mant-GDP. The decrease of fluorescence was detected when different 
concentrations of Rac were mixed with the GEF proteins and excess GDP. The 
calibration of the decrease in fluorescence yielded the kcat value for the GEF proteins. 
 GST-Rac pull-down assay. To check the binding of DHR-2 and DHR-2c with 
Rac, GST-Rac (0.3 nmol) were preloaded on 15 µl of Glutathione Sepharose beads. 
An equivalent amount of DHR-2c was added to the beads with 5 mM EDTA. The 
negative control tube only contained beads and DHR-2c (no GST-Rac). The tubes 
containing these mixtures were rotated at 4°C for half hour and then centrifuged at 
12000 rpm for 1 min. The supernatant was discarded. The beads were washed with 
buffer (three times) and loaded onto an SDS-PAGE gel. Bound DHR-2c was detected 
by Coomassie blue staining.  
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 To check the nucleotide-binding preference, glutathione Sepharose beads 
preloaded with GST-Rac were mixed with DHR-2c and excess GDP/GTP• S in EDTA 
buffer. Excess MgClR2R was added to the solution after 15 minutes and incubated for an 
additional 15 minutes. The beads were washed and binding was detected as described 
above. 
 Indirect Immunofluorescence. The cells were transfect by with plasmids of 
interest and then plated on acid coverslips overnight. The cells were fixed on the 
coverslip in 4% paraformaldehyde for 20 minutes at room temperature and then rinsed 
with PBS three times. Triton X-100 (0.1%) was added to the permeabilized cells. The 
cells were rinsed with PBS an additional three times, and then incubated with primary 
and secondary antibodies in blocking buffer (10% serum in PBS). The cells were 
again washed with PBS (3X) after each incubation.  
 PBD Assays. Cells transfected with plasmids of interest were harvested with 
MBL buffer (Magnesium-containing lysis buffer) containing 50 mM HEPES, pH 
7.5, 150 mM NaCl, 1% Triton, 10% glycerol, 25 mM NaF, 10 mM MgClR2R, 1 mM 
EDTA, 10 µg/ml leupeptin and 10 µg/ml aprotinin. Cell extracts were cleared by 
centrifugation, and the supernatants were used to assess the total amount of Rac.P PThe 
remaining extract was combined with 2 volumes of lysis buffer and the bacterially 
produced Rac/Cdc42- bindingP Pdomain of Pak (i.e. designated as GST-PBD (Upstate)) 
coupled to glutathione beads and incubated for 30 minutes at 4 °C. The beads were 
washed (three times) with lysis buffer and eluted in 5× SDS-Loading sampleP Pbuffer. 
Aliquots of both total cell extracts and the eluents from P Pthe PBD beads were blocked 
by anti-Myc. 
 
42 
 
2.3 Results 
 2.3.1 The DHR-2 domain can activate Rac in vitro 
 The DHR-2 domain of Dock180 was first cloned and characterized in 2002 (2). 
The original DHR-2 domain includes amino acids 1111 to 1657 and is conserved in all 
Dock180 family members. This DHR-2 construct was widely used by all groups who 
were working on the characterization of Dock180 function. It was claimed that the 
DHR-2 domain can activate Rac both in vitro and in vivo(4). However, the expression 
level of recombinant DHR-2 in E.coli is very low.  
 While some of the initial reports on Dock180 appeared, the DHR-2 domain of 
Dock180 was cloned and expressed in bacteria by our laboratory. This DHR-2 
construct is shorter at N-terminus by 70 amino acids compared to the original DHR-2c 
construct described above (2), with an apparent molecular weight of approximately 56 
kDa. We successfully expressed this domain in BL21 DE3 cells using both GST-4T-1 
and pET28a plasmids. Normally, GST-tagged proteins are more soluble than His-
tagged proteins because the GST-tag can help facilitate proper protein folding and 
prevent the protein of interest from forming inclusion bodies. However, for the DHR-2 
domain of Dock180, His-tagged DHR-2 behaviors better in solution than the GST-
tagged protein. Thus, the expression levels of our His-DHR-2 construct (~6mg from a 
2 L culture) are much higher than those for the longer form of DHR-2 that was often 
used in the past (~ 100 µg from a 2 L culture) (Figure 2.3). Therefore, it appears that 
the truncation of the first 70 amino acid enhances the protein expression and increases 
the solubility of the DHR-2 domain. 
 To test the activity of the truncated His-DHR-2 construct, we took advantage 
of a fluorescent read-out using mant-GDP to assay nucleotide exchange on Rac as   
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Figure 2.3 DHR-2 can be expressed in the pET28a plasmid in BL21 DE3 cells. 
Lane1 shows the purified DHR-2 protein after nickel-affinity chromatography. 
The size of DHR-2 is approximately 60 kDa compared to the GST-Rac protein 
(Mr ~ 52 kDa) shown in lane 2.  
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catalyzed by the DHR-2 domain in vitro. Mant-GDP is an analogue of GDP in which 
the ribose 2’-hydroxy or the 3’hydroxy group has been esterified by the fluorescent 
methylisatoic acid. Mant has a maximum excitation wavelength at 355 nm and a 
maximum emission wavelength at 448 nm. We used an excitation wavelength of 340 
nm and an emission wavelength of 440 nm in all of our experiments. Because mant-
GDP shows much higher fluorescence when bound to GTPases like Rac, compared to 
when it is free in solution, the fluorescence read-out provides a highly sensitive assay 
for nucleotide exchange (i.e. the exchange of GDP for mant-nucleotide).   
 The exchange is initiated by mixing mant-GDP with Rac (or Cdc42 or their 
mutants). Because of the low intrinsic rate of GDP dissociation from Rac, mant-  
fluorescence is not significantly increased in the absence of GEF proteins. After 
adding a Rac-GEF, Rac will form a complex with the GEF, resulting in a weakening 
of the affinity for GDP such that it dissociates from Rac.  
 As depicted in Equation 2.1 above, mant-GDP can replace the dissociated GDP 
on Rac, giving rise to a fluorescence increase. Figure 2.4 shows that there was no 
significant increase in mant-fluorescence when GST-Rac was added to a solution 
containing mant-GDP. After DHR-2 was added, the mant-fluorescence increased 
rapidly. This in vitro fluorescence GEF assay confirmed that the recombinant DHR-2 
domain is active and responsible for the GEF activity of the Dock180 protein. 
  
Equation 2.1 
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Figure 2.4 DHR-2 activates Rac in vitro. 100 nM DHR-2 was mixed with 600 nM 
Rac1 in HMA buffer with 1 µM Mant-GDP. Nucleotide exchange was detected by 
monitoring increase in mant-fluorescence. The addition of EDTA served as a 
positive control for the GEF assay. It is well established that, EDTA weakens the 
affinity of small GTPases for GDP and therefore the presence of excess GTP, 
EDTA stimulates GDP-GTP exchange. 
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 We also confirmed that DHR-2 showed the characteristics of a GEF by using 
an in vitro pull-down assay. This assay takes advantage of the limit Cdc42/Rac-
binding domain of the PAK protein (called the PBD) which is fused to GST. GST-
beads pre-loaded with GST-PBD protein can bind and pull-down GTP-bound Rac, but 
not GDP-bound Rac. Using this assay, we found that the DHR-2 domain can promote 
GDP-GTP exchange on Rac. Specifically, Figure 2.5 showed that much more GTP 
was loaded onto Rac (lane 3) in the presence of DHR-2c compared to the amount of 
Rac-GTP formed in the absence of DHR-2 (lane 2). 
 Dock180 and its functional domain DHR-2 were reported to show Rac-specific 
activity. Using the mant-fluorescence assay for nucleotide exchange, we confirmed 
that the DHR-2 domain was unable to activate Cdc42 under conditions where it clearly 
activated Rac (Figure 2.6).  
 As a GEF protein, the DHR-2 domain preferentially binds to nucleotide-free 
Rac. The GST-Rac pull-down assay showed that the binding of DHR-2 to nucleotide-
free Rac (Figure 2.7 lane 2) is much stronger than to either GDP- or GTP-bound forms 
of Rac (lanes 3 and 4).   
 Our preliminary data suggested that the DHR-2 domain can be well expressed 
in E.coli. However, the DHR-2 domain was still only partially purified following 
nickel-affinity chromatography (see Figure 2.3). A significant effort was made to 
improve the purification of DHR-2. However, when we applied the protein (following 
affinity column) to a G200 gel-filtration column, equilibrated in 20 mM Tris-HCl 
pH8.0 and 100 mM NaCl, the majority of DHR-2 was found in the void volume, 
indicating that it aggregated during purification. We found that the aggregation was 
caused by the instability of the DHR-2 domain in low salt solution. After we gradually 
increased the concentration of NaCl in the buffer, a portion of DHR-2 was eluted 
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Figure 2.5 In vitro PBD assay showing that recombinant DHR-2 promotes the GTP-
bound form of Rac. 1 µg His-Rac and 200 ng DHR-2 were incubated with excess 
GTP in HMA buffer with 25 µl PBD-linked beads for 30 minutes. The beads were 
washed several times and the Rac-GTP bound to the PBD beads was detected by 
western blotting with an anti-His antibody. Lane 3 showed that GTP loading on Rac 
was much greater in the presence of DHR-2 compared to when DHR-2 was not 
present ( lane 2).  
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Figure 2.6 DHR-2 specifically activates Rac. Equal concentrations of Rac and 
Cdc42 were mixed with DHR-2 and mant-GDP. Rac showed a significant 
fluorescent change in the presence of DHR-2, while Cdc42 did not show detectable 
mant-GDP binding due to its exchange for GDP on Rac. EDTA servers as a positive 
control as it stimulates GDP-GTP exchange on small GTPases. 
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Figure 2.7 DHR-2 selectively bound to the nucleotide-free (NF) form of Rac. 
GST-Rac was immobilized on GST-beads and preloaded with GDP or GTP, or 
incubated in the absence of nucleotide. Equivalent mounts of DHR-2 were added 
to each incubation. The binding of DHR-2 to Rac was detected by Coomassie blue 
staining. The DHR-2 domain binds more effectively to nucleotide-free Rac (lane 
2) compared  to either GDP or GTP-bound Rac (lanes 3 and 4).   
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through gel-filtration as a monomer although the majority of the protein was still 
aggregated. The amount of monomeric DHR-2 was not sufficient for further 
purification and characterization. We also tried to form a complex between DHR-2 
and Rac to see whether Rac can help stabilize DHR-2. The results showed that the 
complex had a similar tendency to aggregate. Because of its instability in low salt 
solution and the problem with aggregation, it has not been possible to perform a 
rigorous structure-function characterization of this GEF domain. To overcome this 
technical difficulty, we attempted to look for a shorter (limit) functional domain of 
Dock180. 
 
 2.3.2 A new limit DHR-2 domain was discovered 
 As we have described above, although the DHR-2 domain can be well 
expressed in bacteria and activate Rac in vitro, it aggregates in low salt solution. We 
suspected that a hydrophobic region on DHR-2, which was normally involved in an 
interaction with another region of full-length Dock180, became exposed in DHR-2 
and underwent aggregation. If the region on DHR-2 responsible for aggregation does 
not influence its GEF activity, then truncation of this region may help improve the 
stability of the resultant DHR-2 domain construct. 
 Secondary structural analysis using J-pred revealed that there are two sub-
domains in DHR-2 (Figure 2.8). The first sub-domain consists of amino acids 1178-
1335 at the N-terminal of DHR-2 (from here on designated DHR-2n). This region is 
comprised entirely of • -helices. The second sub-domain begins at amino acid 1336 
and extends to the C-terminus of DHR-2 (designated DHR-2c) and is comprised of • - 
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Figure 2.8 Secondary structural predictions of the DHR-2 domain of Dock180 
using J-pred revealed two different sub-domains (residues1178-1334 and 1335-
1657).  
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helices, ß-strands and random coils. It was suggested that there is a hypothetical DH 
domain (amino acids 1111 to 1335) and a PH domain (amino acid 1395 to 1515) 
within the DHR-2 domain (4). The hypothetical DH domain within DHR-2 was based 
on the fact that the typical DH domains of Dbl-family GEFs are also comprised of • -
helices with an average size of approximate 200 amino acids. However, the sequence 
similarity between the DH domains and DHR-2n is quite low and it was impossible to 
convincingly align the DH domains of Dbl-GEFs with DHR-2n. Moreover, the 
hypothetical DH or PH domains of DHR-2 failed to exhibit GEF activity towards Rac 
when they were expressed alone in E.coli. This led to the suggestion that the entire 
DHR-2 domain is essential for Rac activation. However, a construct containing the C-
terminal 150 amino acids of DHR-2 had not been previously examined for GEF 
activity. During our attempt to establish a stable functional sub-domain of DHR-2, we 
prepared a construct comprised of the C-terminal 150 amino acids of DHR-2 
(designated as DHR-2c in Figure 2.9). DHR-2c and a construct comprised on the 
amino-terminal portions of DHR-2 (DHR-2n) were cloned into the pET28a plasmid 
and both constructs were expressed in BL-21 DE3 cells. The recombinant proteins 
were purified as described in the Methods section. Both of the sub-domains were 
tested for their ability to activate Rac in vitro. Mant-exchange assays showed that the 
DHR-2n region was unable to activate Rac, as previously reported (4). However, to 
our surprise, the DHR-2c sub-domain showed high GEF activity toward Rac (Figure 
2.10).   
 Our results demonstrated that the hypothetical DH domain bears no functional 
similarity to the classical DH domain of Dbl-GEFs, but rather the C-terminal region of 
DHR-2 contains the GEF activity. In particular, amino acids 1515 to 1657 were shown 
to be essential for GEF activity. We also tried to express both the regions 1335-1515
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Figure 2.9 Schematic representations of the various DOCK180 and DHR-2 
constructs that were used to assay in vivo and in vitro Rac-GEF activity.  
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Figure 2.10 DHR-2c activates Rac in vitro. 600 nM DHR-2c and DHR-2n were 
incubated with 600nM Rac and 1 µM mant-GDP. DHR-2c showed GEF activity 
towards Rac, similar to DHR-2, while DHR-2n did not show any ability to 
activate Rac.  
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and 1516-1657. Neither of these regions showed GEF activity toward Rac. Very 
recently, the X-ray structure of a complex between Zizimin1 (Dock9) and Cdc42 was 
determined by Barford’s group (5). Zizimin1 is in the same superfamily with Dock180 
and its secondary structure is similar to Dock180 and Zizimin1. Because of these 
similarities, the mechanisms for the GEF activities of Dock180 and Zizimin1 might be 
similar. The tertiary structure of the Zizimin1-Cdc42 complex shows that the region 
corresponding to DHR-2n is not involved in binding Cdc42, consistent with our 
finding that DHR-2n does not contribute to Rac activation (5). The actual contact 
regions between Zizimin1 and Cdc42 align with several areas within DHR-2c, 
involving residues 1335-1515 and residues 1516-1657. The detailed interactions will 
be presented in Chapter 3. 
  
 2.3.3 DHR-2c shows similar GEF activity as the DHR-2 domain 
 The truncated GEF sub-domain of Dock180 (DHR-2c) that will be described 
throughout the remainder of this study is comprised of amino acids 1335 to 1657. The 
size of DHR-2c is approximate 37 kDa which is nearly 200 amino acids shorter than 
the original DHR-2 domain. DHR-2c is highly active as a Rac-GEF. However, a 
number of questions existed whether this construct fully accounts for the Rac-GEF 
capability of Dock180, and if so, how it functions as a GEF.   
 DHR-2c can be well expressed in BL-21 DE3 cells using the pET-28a plasmid, 
with a yield that is significantly higher than that for the DHR-2 domain. 
Approximately 15 mg of DHR-2c protein can be obtained from a 2 liter culture 
compared to 5 mg of protein for DHR-2. DHR-2c can be further purified by a series of 
chromatography steps starting with nickel-affinity chromatography, followed by ion-
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exchange and gel-filtration chromatography. SDS-PAGE showed that DHR-2c is 
stable in low salt solution, i.e. at 100 mM NaCl (Figure 2.11). Under these conditions, 
the majority of the DHR-2c exists as a monomer and is better than 95% pure. Purified 
DHR-2c runs as a doublet on SDS PAGE, perhaps as a result of some limited 
digestion (also, see Appendix). 
 In order to compare the GEF activity of DHR-2c with DHR-2, we needed a 
purified preparation of recombinant DHR-2. We found that gradient elution from a 
Nickel-affinity chromatography with imidazole yields a DHR-2 preparation that is ~85% 
pure. 
 Mant-nucleotide exchange assays (Figure 2.12) showed that, when assaying 
approximately equal amounts of DHR-2 and DHR-2c, the nucleotide-exchange rates 
of Rac were nearly identical, whereas, DHR-2n showed no detectable Rac-GEF 
activity. This indicated that the DHR-2c sub-domain is sufficient for full Rac-GEF 
activity. The fact that DHR-2n, which is also highly conserved among members of the 
Dock180 family, has no influence on nucleotide exchange raises the question of what 
is the function of this region. Recently, based on the structure for the Zizimin1-Cdc42 
complex (5), it was suggested that the DHR-2n region of Zizimin1 is responsible for 
the dimerization of Zizimin1 and is important for the function of the DHR-2 domain 
of Zizimin1, although it does not directly interact with Cdc42. Disruption of the 
dimerization of DHR-2n through mutagenesis significantly decreased the GEF activity 
of the DHR-2 domain of Zizimin1. However, base on our results, the DHR-2n 
construct from Dock180 does not have such a function. First, the DHR-2 domain does 
not undergo dimerization. While DHR-2 has a tendency to aggregate, the non-
aggregated portion remains as a monomer as indicated by gel-filtration
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Figure 2.11 DHR-2c is stable in low salt solution. SDS PAGE showed that most 
of the DHR-2c eluted as a monomer through gel-filtration column, with a small 
amount being aggregated.  
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Figure 2.12 The DHR-2c and DHR-2 domain shows similar GEF activity toward 
Rac. Equal concentrations (600 nM) of DHR-2c (red curve) and DHR-2 (black 
curve) were mixed with Rac (600 nM) and mant-GDP (1 µM). The initial 
reaction rate and the saturation level were approximately same for both 
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chromatography. Second, the absence of the amino-terminal portion of the DHR-2 
domain (corresponding to DHR-2n) does not affect the GEF activity of DHR-2c. One 
possibility is that DHR-2n may contribute to the auto-inhibition of Dock180 by 
providing the binding area for the SH-3 domain, with this interaction blocking access 
to the binding site for Rac. We hope to test this possible mechanism in the near future. 
 
 2.3.4 DHR-2c showed high specific GEF activity toward Rac 
 Similar to the case for the DHR-2 domain, DHR-2c shows GEF activity 
specifically toward Rac. DHR-2c prefers to bind to the nucleotide-free form Rac 
instead of the GDP- or GTP-bound forms of the GTPase (Figure 2.13) 
 The structure of DHR-2c is expected to differ from those of the DH domains of 
Dbl-family GEFs, i.e. based on the known structure of Zizimin1 and Cdc42, we 
assume that there are two possible mechanisms used by DHR-2c to catalyze 
nucleotide exchange. The intrinsic nucleotide exchange of GDP for mant-GDP is slow 
(Pathway I). One possible mechanism is that, when DHR-2c is present, it first forms a 
complex with Rac-GDP, which triggers the removal of MgP2+P and increases the off-rate 
for the dissociation of GDP. The nucleotide-free Rac complex then binds to mant-
GDP which can be detected by monitoring the increase in mant-fluorescence. DHR-2c 
then dissociates from the Rac-mant-GDP and goes on to target a new Rac molecule 
(Pathway II-1). However, there is a second possibility, namely, that prior to the 
dissociation of GDP from Rac (i.e. when Rac is bound to DHR-2c), a second  
nucleotide (i.e. mant-GDP) binds and helps trigger the release of the GDP molecule 
(Pathway II-2). In either case, the total amount of Rac which binds to GDP or mant-
GDP depends on the initial concentration of GDP and mant-GDP in solution. DHR-2c 
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Figure 2.13 DHR-2c binds tightly to nucleotide-free Rac. Similar to full-length 
DHR-2, the binding of DHR-2c to nucleotide-free Rac is much stronger than to 
either GDP-bound or GTP-bound Rac.  
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Figure 2.14 The pathway representing intrinsic nucleotide exchange (Pathway I) 
and the two possible pathways for DHR-2c-catalyzed nucleotide exchange 
(Pathway II-1 and II-2).  
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is able to act in a catalytic fashion to stimulate nucleotide exchange on Rac. Figure 
2.15 shows that, when equivalent amounts of Rac-GDP and mant-GDP were mixed 
with different concentrations of DHR-2c (while maintaining Rac-GDP in excess), 
increasing the concentration of DHR-2c only affects the initial rate for nucleotide-tide 
exchange and not the total amount of Rac that is activated. 
 The nucleotide exchange of GDP for mant-GDP on Rac, as catalyzed by DHR-
2c, is reversible (Pathway II in Fig 2.14). However, if a substantial excess of GDP or 
mant-GDP is present in solution, Pathway II can be considered to be irreversible. 
Under such conditions, it is possible to determine turnover rates for DHR-2c-catalyzed 
nucleotide exchange on Rac. Specifically, this can be done by measuring the 
fluorescence increase that accompanies the exchange of GDP for mant-GDP on Rac, 
under conditions of excess mant-GDP, or by monitoring the loss of mant-fluorescence 
when exchanging mant-GDP for GDP (i.e. the reverse reaction) when GDP is used in 
high excess. However, there are some technical challenges when using the former 
approach because of the background fluorescence contributed by free mant-GDP, and 
so for many of our studies we chose to monitor the changes in mant-fluorescence that 
accompany the exchange of mant-GDP for GDP. As shown in Figure 2.16, when a 
solution containing Rac-mant-GDP was incubated with a large excess of GDP, the rate 
of nucleotide exchange was slow. Addition of DHR-2c (at concentrations much lower 
than Rac-mant-GDP) significantly accelerated the reaction. After mixing 20 nM DHR-
2c and several different concentrations of Rac-mant-GDP (200 nM to 4 µM) with 100 
µM GDP, we obtained a series of fluorescent traces and calculated their corresponding 
initial rates (v). Using the Michaelis-Menton equation, we plotted 1/ v (normalized to 
the DHR-2c concentration) against 1/[Rac-mant-GDP] (Figure 2.17). We obtained a 
Km (half-maximal saturation) value of at 3.3 µM and a maximal rate of dissociation 
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Figure 2.15 DHR-2c activates Rac catalytically. Fluorescence tracings obtained 
when incubating 3 µM Rac with decreasing concentrations of DHR-2c, as 
indicated, in the presence of 1 µM Mant-GDP. The control trace was obtained 
when measuring mant-GDP exchange in the absence of DHR-2c.  
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Figure 2.16 Nucleotide exchange was detected by monitoring the fluorescent 
decrease upon mixing Rac-mant-GDP (600 nM) with DHR-2c (60 nM) and 
excess GTP (100 µM)  
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Figure 2.17 The dependence of initial velocity (•) on the concentration of Rac-
Mant-GDP. The reaction contained initially 20 nM DHR-2c, 100 µM GTP and 
various concentrations of Rac-Mant-Rac.  Initial velocity was calculated by 
observing the decrease in fluorescence at 440 nm. 1/•  was plotted against 1/[Rac] 
and fitted to the Michaelis-Menten equation, yielding a Km of 3.3±0.2 µM and a 
kcat  value of 19.8±3.2 /min.  
 
 
80 
 
81 
 
for GDP (kcat) of 19.8/min. This means that DHR-2c can catalyze the exchange the 
nucleotide on 20 molecules of Rac per minute. 
 We also were interested in determining the intrinsic rate of nucleotide 
dissociation from Rac. Fluorescent mant-exchange assays showed that nucleotide-
exchange on Rac in the absence of DHR-2c is very slow. The intrinsic nucleotide 
dissociation constant of Rac, kR-mant-GDP,R is approximately 0.0166/min. By comparing 
the kRcatR and kR-mant-GDP Rvalues, we concluded that the GDP-dissociation rate from Rac is 
increased ~1000 fold when DHR-2c is presented in solution. These results 
demonstrated that DHR-2c was highly active on Rac in vitro.  
 
 2.3.5 DHR-2c activates Rac in vivo  
 There has been are some controversy about whether the DHR-2 domain is 
sufficient to activate Rac in vivo or if it requires Elmo, as has been suggested for the 
full-length Dock180 (6). To establish whether Rac can be activated in vivo by DHR-2c, 
Cos-7 cells were transiently transfected with plasmids encoding HA-DHR-2c and 
Myc-Rac and then plated overnight. Figure 2.18 shows the co-localization of DHR-2c 
and Rac at the plasma membrane and the formation of membrane ruffles due to 
changes in actin cytoskeletal organization. This demonstrated that the DHR-2c domain 
can activate Rac in Cos-7 cells. To further confirm that Rac is activated by DHR-2c in 
cells. Lysates were prepared and incubated with GST-PBD preloaded onto glutathione 
beads. Figure 2-19 shows that greater amounts of Rac-GTP can be precipitated by 
GST-PBD from cells expressing DHR-2c compared to control cells.
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Figure 2.18 Rac and DHR-2c co-localize in membrane ruffles.  Indirect 
immunofluoresence of Cos-7 cells cotransfected with myc-Rac and HA- DHR-2c.  
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Figure 2.19 PBD assay demonstrates activation of Rac in vivo by DHR-2c. GTP-
bound Rac was affinity precipitated with PBD beads from Cos-7 cell lysates that 
had been transiently transfected with vector, myc-Rac-WT, myc-RacQ61L, or 
RacWT+HA-tagged DHR-2c.  Bottom row of immunoblot shows the relative 
amounts of activated Rac under described conditions. 
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2.4 Discussion 
 Since Dock180 was discovered in 1992, a significant amount of effort has been 
put into the investigation and characterization of this new Rho-GTPase GEF and its 
other family members. As a Rac-specific GEF, Dock180 was found to be involved in a 
number of biological pathways by regulating the activity of Rac. It was reported to be 
able to trigger GDP-GTP exchange on Rac both in vitro and in vivo. The functional 
domain of Dock180 is called the DHR-2 domain and is fully responsible for the GEF 
activity of Dock180. All the DHR-2 domains of Dock180 family members have been 
found to activate Rac, Cdc42 or both of these GTPases. None has been shown to 
activate Rho. The reason for this is not yet clear. 
 The DHR-2 domain is conserved throughout the Dock180 family; however, the 
similarity between different sub-domains is quite low. Recently, the structure of the 
DHR-2 domain of one family member, Dock9 (Zizimin1), was reported (5). However, 
based on the structural information obtained for Dock9, it is still very hard to predict 
the structure of Dock180 and the mechanism by which it activates Rac, because of the 
low sequence similarity (~19%) between Dock9 and Dock180. Several groups have 
been working on functional studies of the DHR-2 domain. Because of its low 
expression levels in E.coli, in vitro data has been difficult to obtain. 
 In our laboratory, we discovered a limit DHR-2 domain (DHR-2c), which is 
shorter by 200 amino-acids compared to the original DHR-2 domain. It still exhibits 
full GEF activity toward Rac. Based on the published data, as well as our results, the 
DHR-2 domain of Dock180 is the most active domain of the family. The kcat of DHR-
2c is ~20/min which is 1000-fold greater than the intrinsic nucleotide dissociation rate 
of Rac. Even when compared with Dock9, a Cdc42-GEF, DHR-2c is 30-fold faster 
than the DHR-2 domain of Dock9. The GEF activities of the DH domains of classic 
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Dbl-GEFs are variable. The activities of some Dbl-GEFs can barely be detected in 
vitro. Based on the available literature, DHR-2c shows higher GEF activity than the 
Dbl-GEFs (Figure 2.20). In Figure 2.20, the GEF activity of DHR-2c is compared to 
three members of the Dbl-GEF family that are specific for Rac. GEF-H1 is the most 
active GEF for Rac among the three Dbl-GEFs, with DHR-2c showing even greater 
GEF activity than GEF-H1. Why Dock180 shows so high activity toward Rac is not 
well understood. The main function of Dock180 is related with Rac-mediated 
phagocytosis. Because the process of phagocytosis is only around 5 to 10 minutes 
after the ‘eat-me’ signals are sent out by apoptotic cells, high-efficient Dock180 can 
quickly activate Rac in the cell. Rac-mediated ruffle formation can surround the 
apoptotic cell and prevent the poisonous extent to be released outside of cells. 
 The DHR-2c domain of Dock180 can activate Rac both in vitro and in vivo. 
However, the same region from other family members can not fully activate their 
corresponding GTPases. The DHR-2c region of Dock9 showed much weaker activity 
toward Cdc42 compared to the full-length DHR-2 domain because the DHR-2n region 
is reported to be important for the dimerization of Dock9 (5). We cloned the same 
regions from Dock7 and Dock11 and found that neither showed GEF activity toward 
Cdc42 or Rac. Thus, DHR-2c of Dock180 appears to be a unique region in its ability 
to exhibit high GEF activity.  
 As a GEF for Rac, Dock180 is tightly regulated in cells. Dock180 participates 
in a number of Rac-dependant signaling pathways and is recognized as one of the 
main activators of Rac. As mentioned above, there are two large superfamilies of 
GEFs containing more than 70 members each that activate Rho GTPases. This raises 
the common question of why are so many Rho-GEFs needed for the same GTPase? Or 
put another way, why is the Dock180 family needed when there is already a large  
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Figure 2.20 DHR-2c showed higher GEF activity than the DH domain of Dbl-
GEFs. A) 200 nM Rac1 loaded with mant-GDP was incubated with 200 nM 
DHR-2c at room temperature in an exchange buffer containing 20 mM Hepes 
(pH 8.0), 5 mM MgCl2 and 0.5 mM GTP. DHR-2c caused a faster decrease in 
mant-fluorescence compare to the DH domains of TrioN, GEF-H1 and Tiam1 as 
shown in Figures B-D, respectively. Figures B-D were taken from Zheng and 
colleagues’ paper (1).  
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family of Dbl-GEFs? Are their significant differences in their mechanisms of action? 
How do Rho-GTPases select a particular GEF for in a specific signaling pathway? In 
the next chapter, some of our recent work will be presented that considers the 
similarities and differences of Rac activation by Dock180 and Tiam1, which are 
representative members of the Dock180 and Dbl-GEF families. 
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CHAPTER 3 
RECOGNITION OF SPECIFIC BINDING BETWEEN RAC AND DHR-2C 
3.1 Introduction 
 Members of the two large families of Rho-guanine nucleotide exchange factors 
(GEFs), the classical Dbl-GEFs and the more recently discovered Dock180 family, 
play vital roles in cellular signal transduction. However, when comparing their 
primary sequences and three-dimensional structures, it is clear that the Dbl-GEFs and 
Dock180 family members are quite distinctive from each other. Since the x-ray 
structure for the complex formed between Tiam1 and Rac was first solved in 2000 by 
Sondek’s laboratory (1), a number of structures of Dbl-GEF have been determined and 
the mechanism by which they activate Rho GTPase activation by Dbl-GEFs has been 
established based on the structural information. The DH-domains of all the known 
Dbl-GEFs comprise • -helices only, and their contact regions with Rho GTPases are 
very similar.  
 Tiam1 is a representative of the Dbl-GEF family, and a good deal of work has 
been done to investigate its interaction with and activation of Rac.  It has been 
reported that the main contact regions for Tiam1 on Rac are located in the switch I and 
switch II regions as shown in Figure 3.1. In the switch I region, mutagenesis studies 
have shown that the Cdc42 (Tyr32Ala) mutant retained the ability to bind to Tiam1 
but was unable to be activated by the GEF, while the Cdc42 (Asp38Ala) and Cdc42 
(Asn39Ala) mutants lost their ability to bind Tiam1. The Cdc42 (Gln61Leu) and 
Cdc42 (Tyr64Ala) mutants, which contain substitution within switch II, were also 
found to be unable to couple to the DH domain of Tiam1(2). These results indicated 
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Figure 3.1 The main contact areas of Rac with Tiam1 are located in switch I, 
switch II and the ß2-ß3 region. (A) Cdc42 (Tyr32Ala) mutant retained the ability 
to bind to Tiam1 but was unable to be activated by the GEF, while the Cdc42 
(Asp38Ala) and Cdc42 (Asn39Ala) mutants lost their ability to bind Tiam1. (B) 
Single-substitutions at Glu61 and Tyr64 all significantly affect the Rac binding 
and the activation by Tiam1. (C) Trp56 of Rac is the only residue which is 
responsible for the Dbl-GEF specific recognition.  
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that the switch I and switch II regions of Rac are both important for Tiam1 binding 
and activation.  
 In addition to the switch I and switch II regions, there is another key residue, 
Trp56, which is located within the • 2-• 3 region of Rac. It was reported to not only be 
critical for the Tiam1 interaction, but it is the only residue that serves to ensure that 
Rac distinguishes Tiam1 from a Cdc42-specific GEF i.e. Intersectin. Changing this 
tryptophan to phenylalanine (i.e. the corresponding residue in Cdc42) enables Rac to 
be recognized by Cdc42-GEFs (2).  
 The activation mechanism of Rac/Cdc42 by Dock180-GEFs is still not well 
understood. Only very recently has information become available for the DHR-2 
domain of the Dock180-GEFs. Yang and colleagues reported the structure of the 
complex formed between the DHR-2 domain of Zizimin1 (Dock9) and Cdc42 (3). 
Some information regarding the sites of contact between Zizimin1 and Cdc42 can be 
extracted from the 3D structure of the complex. However, those residues that are 
really important for the interaction are still not known. 
 
3.2 Methods 
 Plasmids. Rac, Cdc42 and DHR-2c mutants were generated from plasmids 
encoding wild-type Rac, Cdc42, and DHR-2c, using site-directed mutagenesis kits 
purchased from Stratagene.  
 Protein Expression and Purification. Single colonies of E.coli BL21 (DE3) 
containing target plasmids were inoculated in 10 ml of LB media with 50 µg/ml 
kanamysin/Carbenicillin (RPI) and cultured overnight at 37°C.  These small cultures 
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were subsequently used to inoculate 1 L LB media with 50 µg/ml kanamysin/ 
carbenicillin in a shaking incubator at 37°C. The large-scale cultures were incubated 
to a density of OD600=0.6 and induced by IPTG (RPI) (final concentration = 200 µM) 
at room temperature overnight. Bacteria were harvested by centrifugation at 5000 rpm 
for 10 minutes and the pellets were re-suspended in lysis buffer (20 mM Tris-HCl PH 
8.0, 5 mM MgCl2, 500 mM NaCl) with 10 µg/ml leupeptin and 10 µg/ml aprotinin.  
 For DHR-2c and its mutants, the suspensions were sonicated and the lysates 
were cleared by centrifugation at 20000 rpm for 30 minutes. The supernatants were 
collected and incubated with nickel chelate beads (Amersham) for 30 minutes on ice. 
The beads were washed with lysis buffer containing 40 mM imidazole until no 
significant protein was detected in the wash buffer. The proteins were eluted with lysis 
buffer containing 200 mM imidazole, concentrated to 200 µM, and stored at -80°C for 
further use. 
 Rac, Cdc42 and their mutants were expressed using similar procedures as 
described above and the supernatants were collected and applied to a glutathione-
sepharose column. Unbound proteins were washed off by lysis buffer and target 
proteins were eluted using the same buffer with 10 mM glutathione. The eluted 
proteins were applied to P-10 desalting column to remove glutathione and 
concentrated to 300 µM.  
 In vitro Guanine Nucleotide Exchange Assay. All fluorescence measurements 
were performed using a Varian Ecilpse Fluorescence Spectrophotometer. Samples 
were stirred continuously and thermostated at 25 °C in HMA buffer (20 mM HEPES 
pH 8.0, 5 mM MgCl2 and 1 mM NaN3).  In vitro GEF assays using mant-GDP as a 
probe to monitor fluorescent changes accompanying nucleotide exchange were 
performed on recombinant GTPases. Mant-GDP was added to HMA buffer to a final 
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concentration of 1 µM. Different concentrations of Rac/ Cdc42 and their mutants were 
added together with various concentrations of the DHR-2c domain of Dock180 and 
the DH-PH domain of Tiam1. The Mant-GDP fluorescence changes were monitored 
using an excitation wavelength of 340 nm and an emission wavelength of 440 nm at 
25°C. Each measurement was repeated at least three times.  
 
3.3 Results 
 3.3.1 Trp 56 of Rac is important for Dock180 binding and activation 
 As a first step toward investigating the mechanism by which Dock180 
activates Rac, we examined the effects of NSC 23766, a small molecular inhibitor of 
Rac activation. NSC 23766 was originally identified using a ‘virtual screen’ for Rac 
inhibitors from the National Cancer Institute Database (4). The compound was 
predicted to dock into the active pocket of Rac, surrounding tryptophan 56 and thereby 
blocking the interaction of Rac with traditional Dbl-family GEFs like Tiam1. This 
compound was experimentally tested for its ability to inhibit the actions of Tiam1 and 
another GEF, LBC toward Rac. The results showed that NSC 23766 was capable of 
both in vivo and in vitro inhibition of the Rac-GEF activity of Tiam1 and LBC. 
However, the inhibition observed in vitro was relatively weak.   
 We have tested the inhibitory ability of NSC 23766 toward Dock180. Varying 
concentrations of NSC 23766 were premixed with Rac and mant-GDP for 10 minutes 
and then DHR-2c was added to the mixture. The activation of Rac was monitored by 
tracking changes in mant-fluorescence accompanying nucleotide exchange. The 
nucleotide exchange rates were much lower when NSC 23766 was present, compared 
to the control (which lacked the inhibitor). NSC 23766 showed similar inhibitory 
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ability against the DHR-2c domain as seen against Tiam1. Pull-down assays also 
showed that NSC 23766 disrupted complex formation between DHR-2c and Rac. 
However, the inhibition was not complete even when the concentration of NSC 23766 
was in 200-fold excess relative to Rac. Overall, our results seemed to indicate that 
NSC 23766 competes with DHR-2c for the binding to Trp56 which partially blocks 
the interaction between DHR-2c and Rac.  
 To further confirm the importance of this tryptophan residue for the binding of 
Rac to DHR-2c, Trp56 of Rac was changed to phenylalanine (the corresponding 
residue in Cdc42). Fluorescence exchange assay showed that this single substitution 
totally abolished Rac activation by DHR-2c (Figure 3.2A) and also eliminated the 
interaction between Rac and DHR-2c. We also confirmed that nucleotide exchange on 
this Rac mutant can be triggered by adding EDTA, which means that it is still capable 
of nucleotide binding. These results demonstrated that Trp56 of Rac is critical for the 
interaction with both Dock180 and Dbl-family Rac GEFs.  
 Trp56 is located in the • 2-• 3 loop of Rac. There are some other residues in this 
region which are also reported to be important for Dbl-GEF recognition. Mutation of 
Gly54 to alanine makes Rac insensitive to Tiam1. To test whether Gly54 of Rac is 
also important for DHR-2 binding, we made the same Rac (Gly54Ala) mutant.  
Fluorescence mant-assays confirmed that nucleotide exchange on this mutant can not 
be triggered by the DHR-2c domain. These results demonstrated that the ß2-ß3 region 
of Rac is an important docking area for DHR-2c, similar to the case for DH domains 
of Dbl-like GEFs.   
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Figure 3.2  Trp56 of Rac is critical for both Dock180 and Tiam1 recognition. 180 
nM DHR-2c (A) or 15 µM DH-PH domain of Tiam1(B) were mixed with same 
concentration (600 nM) of wild-type Rac or the Rac(Trp56Phe) mutant.  Rac 
(Trp56Phe) was not able to respond to either the DHR-2c domain of Dock180 or 
the DH-PH domain of Tiam1.  
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 3.3.2 Trp56 of Rac specifically recognizes Met1524 of Dock180 
 The next question that we were interested in addressing was what are the 
corresponding residues on DHR-2 which interact with and recognize Gly54 and Trp56 
of Rac. The x-ray structure for the Zizimin1-Cdc42 complex provides us with some 
clues regarding the nature of the Rac-DHR-2 interaction. From the structure (Figure 
3.3), the only residues that are close to Gly54 and Phe56 of Cdc42 are Leu1940 and 
Gln1943 of Zizimin1.  In particular, the methyl group of Leu1940 is in close 
proximity (~3.5 A) to both the benzene ring of Phe56 and the backbone of Gly54. It 
may form hydrophobic interactions with these two residues. More importantly, this 
leucine residue is conserved in all Dock D subfamily members (i.e. specific GEFs for 
Cdc42). We hypothesized that this leucine residue is necessary for specifically 
recognizing the phenylalanine residue of Cdc42, while Met1524 of Dock180, which is 
conserved at the same site on other Dock180-GEFs (Figure 3.4), is responsible for 
Rac-GEF specificity. Based on our prediction, Met1524 of DHR-2c should contact 
directly Trp56 of Rac, and if we mutated this residue, the interaction between DHR-2c 
and Rac should be severely influenced. In order to confirm this, we mutated Met1524 
of DHR-2c to alanine. Removal of the side chain of methionine significantly alters the 
GEF activity of DHR-2c. Fluorescence mant-assays showed that the GEF activity of 
the DHR-2c (Met1524Ala) mutant toward Rac is only about 20% of the Rac-GEF 
activity of wild- type DHR-2c (Figure 3.5). We then examined whether the loss of the 
GEF activity is due to the inability of the DHR-2c (Met1524Ala) mutant to bind to 
Trp56 of Rac. We changed Met1524 to leucine which is the corresponding residue in 
Zizimin1 (i.e. Leu1940). Although this represented a conservative substitution, the 
resultant DHR-2c (Met1524Leu) mutant was incapable of activating Rac (Figure 3.5), 
similar to the case for the DHR-2c (Met1524Ala) mutant.  This told us that Rac is very   
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Figure 3.3 Structure of DHR-2 (Zizimin1)-Cdc42 complex and the detail binding 
area between the ß3 region of Rac and the DHR-2c domain of Zizimin1. 
Leu1940 of Zizimin1 is in close proximity (~3.5 A) to the benzene ring of Phe56 
and the backbone of Gly54. Q1943 of Zizimin1 is also close to Phe56 of Rac.  
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Figure 3.4 Alignment the region of DHR-2 which binds to the • 2-• 3 region of 
Rac. Met1524 of Dock180 is conserved in all Dock180-family members except 
in the Cdc42-specific GEFs (leucine is present at the corresponding position in 
Cdc42) . 
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Figure 3.5 Met1524 of DHR-2c is critical for Rac activation. Mutation of 
Met1524 of DHR-2c significantly reduced its GEF activity. DHR-2c, DHR-2c 
(Met1524Leu), and DHR-2c (Met1524Ala) (60 nM, each) were mixed with 600 
nM Rac and 1 µM mant-GDP in HMA buffer. The mant-GDP exchange rates for 
the mutants are about 20% of the exchange rate catalyzed by wild-type DHR-2c.  
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sensitive to the presence of this methionine residue on DHR-2c. More interestingly, 
although the DHR-2c (Met1524Leu) mutant lost 80% of its GEF activity toward Rac, 
it regained the ability to stimulate nucleotide exchange on the Rac (Trp56Phe) mutant. 
As mentioned above, the Rac (Trp56Phe) mutant does not respond to either wild-type 
DHR-2c or the DHR-2c (Met1524Ala) mutant. However, the DHR-2c (Met1524Leu) 
mutant is quite efficient at activating the Rac (Trp56Phe) mutant (Figure 3.6). A 
possible explanation is that changing Trp56 to phenylalanine in Rac disrupts the 
interaction between Trp56 and Met1524 of DHR-2c. As shown in Figure 3.7, 
computer modeling predicts that Trp56 undergo a hydrophobic interaction with 
Met1524. If Trp56 is mutated to phenylalanine, because the phenyl ring is much 
smaller than the indole ring, this hydrophobic interaction may not occur. However, the 
substitution of Met1524 to Leucine enables an interaction between Phe56 and 
Leu1524 to occur because of the extra methyl group, which is similar to the leucine-
phenylalanine interaction that occurs between Zizimin1 and Cdc42 (Figure 3.3). These 
results demonstrate that Met1524 of Dock180 and Trp56 of Rac are critical residues 
for the Rac-Dock180 interaction. On the other hand, the corresponding interaction 
between a leucine residue on Zizimin1 and a phenylalanine on Cdc42 is essential for 
the GEF activity exhibited by Zizimin1 toward Cdc42. Overall, these findings confirm 
that Trp56 of Rac is responsible for the specific recognition of Dock180 and Tiam1 by 
Rac. 
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Figure 3.6 Met1524 of DHR-2c specifically recognizes Trp56 of Rac. DHR-2c 
(Met1524Leu) activates the Rac (Trp56Phe) mutant. DHR-2c, DHR-2c 
(Met1524Leu), or DHR-2c (Met1524Ala) (600 nM each), were mixed with 600 
nM Rac and 1 µM mant-GDP in HMA buffer. Only DHR-2c (Met1524Leu) 
showed significant GEF activity toward Rac, while both wild-type DHR-2c and 
DHR-2c (Met1524Ala) can not stimulate nucleotide exchange on Rac (W56F). 
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Figure 3.7 Computer prediction of the interaction between Trp56 of Rac and 
M1524 of DHR-2c using Pymol. The Trp-Met hydrophobic interaction in 
Dock180DHR-2c-Rac (Phe-Leu interaction in Dock9DHR-2-Cdc42) may 
contribute to their specific recognition to each other. Mutating Trp56 to Phe56 
disrupts the hydrophobic interaction while mutating Met1524 to Leu1524 
rebuilds the interaction which enables Rac(Trp56Phe) to be activated by DHR-
2c (Met1524Leu) mutant. 
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 3.3.3 Trp 56 of Rac is not sufficient to specifically recognize Dock180 
 Trp56 of Rac and Phe56 of Cdc42 have been reported to be the residues that 
are responsible for the specific interaction of these GTPases with their Dbl-family 
GEFs. Thus, when Trp56 of Rac is changed to phenylalanine, the resultant Rac 
(Trp56Phe) mutant can no longer be recognized by a Rac-specific GEF, whereas it can 
be activated by a Cdc42-GEF of the Dbl family. The reverse is true when Phe56 of 
Cdc42 is changed to Trp56, i.e. Cdc42 can be activated by a Rac-GEF. We have 
already demonstrated Trp56 of Rac is also important for DHR-2c binding and 
activation. However, is this residue all that is necessary for ensuring specificity with 
regards to interaction with Dock180-family GEFs? 
  Both the Rac (Trp56Phe) and Cdc42 (Phe56Trp) mutants were prepared in 
order to compare their abilities to be activated by the DH-PH domain of Tiam1 and the 
DHR-2c domain of Dock180. Mant-GDP-exchange assays (Figure 3.2B) showed that 
the Rac (Trp56Phe) mutant can no longer be activated by the DH-PH domain of 
Tiam1. On the other hand, the Cdc42 (Phe56Trp) mutant is able to couple to the DH-
PH domain of Tiam1 and exhibits a similar rate of nucleotide exchange (~80%) as 
wild-type Rac (Figure 3.8B).  
 While Trp56 of Rac is important for the specific recognition of DHR-2c, the 
Cdc42 (Phe56Trp) mutant is still unable to be recognized by DHR-2c. Figure 3.8A 
shows that the DHR-2c domain is absolutely incapable of stimulating nucleotide 
exchange on the Cdc42 (Phe56Trp) mutant. These results suggest that Trp56 of Rac is 
necessary but not sufficient for specific recognition by DHR-2c. Thus, there must be 
additional residues that also contribute to Dock180-GEF recognition. 
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Figure 3.8 The Cdc42 (Phe56Trp) mutant can not be activated by the DHR-2c 
domain of Dock180 while it can be activated by the DH-PH domain of Tiam1. 
(A) 180 nM DHR-2c was mixed with 600 nM wild-type Rac or the Cdc42 
(Phe56Trp) mutant. Nucleotide exchange can not be stimulated on the Cdc42 
mutant by DHR-2c (compared to wild-type Rac). (B) 15 µM Tiam1 was mixed 
with 600 nM wild-type Rac or the Cdc42 (Phe56Trp) mutant. The nucleotide 
exchange rate for the Cdc42 mutant is similar to that for wild-type Rac 
stimulated by the DH-PH domain of Tiam1.  
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 3.3.4 Another specific interaction is between the Switch I region of Rac 
and the DHR-2c domain of Dock180 
 Given the results described in the preceding section, we set out to search for 
other residues that cooperate with Trp56 in order to mediate the specific interaction 
with DHR-2c. We suspected that candidate residues were those that differed between 
Cdc42 and Rac. It has already been reported that residues downstream from position 
69 on Rac and Cdc42 are not involved in GEF recognition (5). Therefore, wenarrowed 
down the candidates to Ala27, Gly30, Ser41, Ala42, Asn43, Val46, Asp47, Lys49, 
Val51 and Asn52 on Rac (and Lys27, Ser30, Ala41, Val42, Thr43, Ile46, Gly47, 
Glu49, Try51 and Thr52 on Cdc42). Based on the structure of the Zizimin1-Cdc42 
complex, residues 42-51 of Cdc42 do not participate in binding to Zizimin1. Glu49 of 
Cdc42 is in close proximity to Arg1753 of Zizmin1. However, this arginine is also 
conserved in Dock180 and is not present in the DHR-2c construct. Mutagenesis work 
has also shown that mutating residue Ser41 or Asn52 of Rac to the cor-responding 
residues in Cdc42 does not affect its full activation by DHR-2c (data not show). Only 
Ala27 and Gly30 of Rac have been shown to be important for DHR-2 activation. We 
changed Ala27 of Rac to lysine and Gly30 to serine, i.e. the corresponding residues in 
Cdc42. These two mutants can be well expressed in bacteria and are still capable of 
undergoing EDTA-stimulated nucleotide exchange. Fluorescent data (Figure 3.9) 
showed that both mutants significantly lost their ability to be activated by DHR-2c. 
DHR-2c is ineffective at stimulating nucleotide exchange on Rac (Ala27Lys), just as it 
is ineffective with the Rac (Trp56Phe) mutant. The rate for DHR-2c-stimulated 
nucleotide exchange on the Rac (Gly30Ser) mutant is only 20% of that for wild-type 
Rac. These data showed that both Ala27 and Gly30 of Rac are critical for DHR-2c 
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Figure 3.9 Ala27 and Gly30 of Rac are critical for Rac activation by DHR-2c. 
(A) 180 nM DHR-2c was mixed with 600 nM wild-type Rac, Rac (Ala27Lys), or 
Rac (Gly30Ser). The Rac (Ala27Lys) mutant can not be activated DHR-2c and 
Rac (Gly30Ser) was activated weakly by DHR-2c (B) 15 µM Tiam1 was mixed 
with 600 nM wild-type Rac, Rac (Ala27Lys), or Rac (Gly30Ser). Both mutants 
showed similar activation by DHR-2c, as wild-type Rac.  
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binding and the interaction between switch I of Rac and DHR-2c is important for Rac 
activation.  
 The switch I region of Rho GTPases is also an important binding region for 
Dbl-family GEFs, although it is not responsible for specific recognition of the GEF. 
Single residue substitutions in Rac or Cdc42 (i.e. Tyr 32, Asp38 or Asp39) either 
resulted in an inability of Rac to bind to Dbl-family GEFs or abolished the GEF- 
catalyzed nucleotide exchange. However, based on x-ray structure for Tiam1-Rac 
complex, there are no direct interactions between residue 27 or 30 of Rac and Tiam1. 
We tested the activation of Rac (Ala27Lys) and Rac (Gly30Ser) by the DH-PH 
domain of Tiam1. Figure 3.8B shows that both mutations do not affect the Rac 
activation by Tiam1. Ala27 and Gly30 of Rac are not important for Tiam1 binding and 
activation, which is different from DHR-2c.     
 Residue 27 and 30 are divergent residues when comparing Rac and Cdc42, and 
they are important for Rac activation by DHR-2. Although the Cdc42 (Phe56Trp) 
mutant can not be activated by DHR-2c, we were interested in seeing whether 
substitutions at position 27 or 30 of Cdc42, together with a substitution at position 56, 
yielded a Cdc42 double-mutant that can be recognized by DHR-2c. To examine this 
possibility, multiple mutants were prepared were prepared and expressed in E.coli 
including single mutants Cdc42 (Lys27Ala) and Cdc42 (Ser30Gly), double mutants 
Cdc42 (Lys27Ala-Phe56Trp) and Cdc42 (Ser30Gly-Phe56Trp), and triple mutant 
cdc42(Lys27Ala-Ser30Gly-Phe56Trp. Mant-nucleotide exchange assays were 
performed with all these mutants.  As shown in Figure 3.10, All of the single mutants 
can’t response to DHR-2c and neither the Cdc42 (Ser30Gly-Phe56Trp) double-mutant, 
similar to the Cdc42 (Phe56Trp) mutant. However, the Cdc42 (Lys27Ala-Phe56Trp) 
double-mutant was partially activated by DHR-2c.   
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Figure 3.10 Activation of Cdc42 mutants by DHR-2c. Single substitutions at 
residues 27,30 or 56 of Cdc42 do not make Cdc42 responsive to DHR-2c. Only 
the Cdc42 (Lys27Ala-Phe56Trp) double-mutant can be partially (~25% 
comparing to wild-type Rac) activated by DHR-2c. The different Cdc42 mutants 
(600 nM), or wild-type Rac or Cdc42 was mixed with 180 nM DHR-2c. Cdc42 
(Lys27Ala-Phe56Trp) can be activated by DHR-2c while the other Cdc42 
mutants are not capable of being activated by DHR-2c.  
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When compared with the Cdc42 (Phe56Trp) mutant which can be fully activated by 
the Rac-specific GEF Tiam1, the activation of Cdc42 (Lys27Ala-Phe56Trp) by DHR-
2c is poor. However, this is the only Cdc42 mutant that we have found to be 
recognized and activated by DHR-2c. Moreover, the kcat for the activation of Cdc42 
(Lys27Ala-Phe56Trp) by DHR-2c is still higher than the kcat for wild-type Cdc42 
activated by Zizimin1 (3). Taken together, our findings suggest that residue 27 and 56 
work together to specifically couple Rac/Cdc42 to their Dock180-GEFs.  
 
3.4 Discussion 
 For the cases of both Dbl-family GEFs and Dock180-family GEFs, some 
members show strict specificity for Rac versus Cdc42, whereas some members 
activate both GTPases. The sequence similarity between Rac and Cdc42 is very high, 
thus raising the question of how Rac or Cdc42 can be specifically recognized by their 
GEFs. For Dbl-GEFs, it was demonstrated that residue 56 of Rac or Cdc42 is 
responsible for GEF specificity. Changing the tryptophan to phenylalanine on Rac 
makes it capable of being recognized by Cdc42-GEFs, and the converse is true when 
Phe56 of Cdc42 is changed to tryptophan, i.e. the Cdc42 (Phe56Trp) mutant can 
respond to the Dbl-family Rac-GEF Tiam1. Thus, the position 56 residue is entirely 
responsible for imparting specificity with regard to Cdc42 and Rac recognizing their 
specific Dbl-family GEFs.  
 How Rac/Cdc42 specifically recognizes their Dock180-GEFs is still unclear. 
We found that Trp56 of Rac is also critical for Dock180 binding and activation. The 
interaction between Trp56 of Rac and Met1424 of Dock180 plays a key role in the 
ability of Rac to specifically recognize Dock180. However, for Dock180 family 
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members, position 56 in Rac or Cdc42 is not the only residue responsible for GEF 
specificity. We found that Ala27 of Rac (Lys27 of Cdc42) also contributes to GEF 
specificity.  
 We have identified the residue on the DHR-2c (Met1424) that specifically 
interacts with Trp56 of Rac. The critical residues on DHR-2c which bind to Ala27 of 
Rac have still not been determined. From the x-ray structure for the Cdc42-Zizimin1 
complex, there are several residues on Zizimin1 that may contact Lys 27 of Cdc42. 
Ser1813 and Thr1831 of Zizimin1 are both in close proximity to Lys27 of Cdc42 
(~5.5 A) and these two residues are conserved in all Dock180-family Cdc42-GEFs. 
From our data, we can see that Gly30 of Rac is important for DHR-2 binding (Figure 
3.11). However, this residue is not directly involved in specific GEF recognition. The 
double-mutant Cdc42 (Ser30Gly-Phe56Trp) can not be activated by DHR-2c and the 
triple-mutant Cdc42 (Lys27Ala-Ser30Gly-Phe56Trp) did not show any increased 
capability for being activated by DHR-2c compared to Cdc42 (Lys27Ala-Phe56Trp) 
double mutant. The Zizimin1-Cdc42 complex shows that there is an interaction 
between Glu1811 of Zizimin1 and Ser30 of Cdc42. This interaction may also 
contribute to the specific recognition of Zizimin1 by Cdc42. 
 Besides examining those residues that are different between Cdc42 and Rac, 
we also examined the possible roles of some other residues in contributing to DHR-2c 
activation. We changed those residues in switch I, II, and the • 2-• 3 regions which 
were reported to be important for binding to Dbl-family GEFs, as we wanted to see 
whether these residues also interact with DHR-2c. Residues in • 3 strand and switch II 
region of Rac (i.e. Gly54, Trp56 and Glu61) are important for binding to both the 
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Figure 3.10 The contact area between Lys27/Ser 30 of Cdc42 and DHR-2c. 
Ser1813 and Thr1831 of Zizimin1 are both in close proximity to Lys27 of Cdc42 
(~5.5 A), and Gln1811 of DHR-2c possibly interacts with Ser 30 of Rac. And 
both of the residues are conserved in all Cdc42 Dock180-GEFs. 
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DHR-2c and DH domains. In the switch I region, the critical residues which contribute 
to the binding of DHR-2c versus the DH domain are different. Ala27 and Gly30 of 
Rac respond differently to the DHR-2c and DH domains. In addition, we found that 
the Tyr32Ala mutant of Rac loses its sensitivity toward DH domains while it is still 
able to be activated by DHR-2c.  Glu39Ala, another substitution at the end of switch I, 
is unable to be activated by both DHR-2c of Dock180 and the DH domain of Tiam1. 
These data show that switch I region is important for the binding of both Dock180 and 
Dbl-family GEFs. However, the specific binding sites are different for these two 
families of GEFs.  
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CHAPTER 4 
CONCLUSION 
 Rho GTPases participate in a wide range of cellular activities including cell 
mobility, cytoskeletal organization and activation of specific kinases. Rho family 
proteins exist in two different states, a signaling-inactive GDP-bound and a signaling-
active GTP- bound state. In order to switch between these two states, GEFs help 
stimulate the exchange of GDP for GTP on Rho GTPases. 
 Two families of Rho GEFs have already been discovered. The classical Dbl-
family of GEFs consists of more than 60 members in humans with each member  
qsharing a conserved tandem DH-PH domain (1). The newly discovered Dock180-
GEF family consists of 11 members in humans (2). They share very low sequence 
similarity with the Dbl-family and instead share two conserved domains designated as 
the DHR-1 and DHR-2 domains. Within the 11 family members, Dock180 is best 
studied.  
 Various studies have shown that Dock180 and its homologues in Drosophila 
(Myoblast City) and C. elegans (Ced-5) are involved in a number of biological 
processes including actin cytoskeleton reorganization, phagocytosis, cell migration 
and myoblast fusion (3-5). Dock180 was shown to be an upstream regulator of Rac 
and biochemical analysis confirmed that it functioned as a Rac-GEF (6). The DHR-2 
domain of Dock180 was demonstrated to be responsible for its activity.  
 In my thesis work, I was focusing on the biochemical characterization of the 
limit domain (DHR-2c) of Dock180 and investigation of the activation mechanism on 
Rac. The main finding from my thesis research are listed below. 
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1. DHR-2c is a limit sub-domain in Dock180 which functions as a specific 
GEF for Rac. The DHR-2 domain of Dock180 in E.coli is not well behaved in low 
salt solution, making it difficult to purify this functional domain to homogeneity and 
to reliably measure its guanine nucleotide exchange activity. Based on secondary 
structure analysis and homology modeling of the DHR-2 sequence, together with the 
recently published structure of the Dock-9/Cdc42 complex (7), I delineated a limit-
functional domain for Dock180 (residues 1335-1657) that binds its cognate GTPase 
Rac in a manner typical of a GEF. In addition, the ~37 kDa DHR-2c domain showed 
robust activity toward purified Rac in fluorescence-based GEF assays, whereas I 
found no evidence that the amno-terminal half of the DHR-2 domain (residues 1178-
1334) contributes to the overall GEF activity of the DHR-2 domain. In vivo 
experiments have also confirmed that the DHR-2c domain can activate Rac in cells.  
 2. DHR-2c shows high GEF activity compared to other GEFs. In order to 
examine the catalytic potential of the DHR-2c domain, I performed GEF assays under 
conditions of excess Rac GTPase. Different concentrations of purified mant-GDP-Rac 
were mixed with excess GDP and sub-stoichiometric amounts of DHR-2c. Using this 
readout, I estimated a kRcatR value of 19.8/min (0.33/sec) for DHR-2c which is 1000-fold 
faster than the intrinsic GDP-dissociation rate constant for Rac. It is also much higher 
than the activity of most of the Dbl-Rac GEFs and other Dock180 family members.
 3. The Trp56 of Rac specifically recognizes the Met1524 of DHR-2c. In 
order to explore the factors underlying the relative selectivity of the GEF activity of 
DHR-2c towards Rac/Cdc42, I evaluated the importance of Trp 56 of Rac. I found that 
the Rac (Trp56Phe) mutant is activated to <10% of the level of wild-type Rac by 
DHR-2c.  Using the Cdc42-Dock9 x-ray crystal structure as a guide (7), I determined 
that the methyl group of Leu1940 in Dock9 interacts with the phenyl side-chain of Phe. 
This leucine residue is conserved in members of the Dock subfamily D (Dock 9-11 
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which are specific for Cdc42), while in the Rac-specific subfamily A (Dock 1,2, and 5; 
Dock1 being Dock180), the corresponding residue is methionine. I mutated the 
corresponding residue Met1524 to leucine in DHR-2c and found the removal of the 
side-chain of methionine decreases the GEF activity of DHR-2c by ~80%. Conversely, 
the leucine substitution resulted in a five-fold increase in GEF toward the Rac 
(Trp56Phe) mutant.  Taken together, these results provided insight into how Dock180 
versus Zizimin1 discriminate between Rac versus Cdc42. 
 4. Ala 27 and Trp 56 of Rac both contribute to the specific recognition for 
Dock180-family Rac GEFs. Tryptophan 56 of Rac is necessary for DHR-2c binding 
and activation, similar to what has been observed for the DH-domain of Tiam1. 
However, the complementary substitution (i.e. Phe to Trp) at position 56 in Cdc42 is 
not sufficient to allow for nucleotide exchange catalyzed by DHR-2c which indicates  
that additional contacts are necessary for full GEF activity. Further mutagenesis 
experiments showed that Ala 27 of Rac is also important for specific recognition by 
Dock180. Fluorescence GEF assays demonstrated the Rac (Ala27Lys) mutant was 
severely impaired in its ability to functionally couple to DHR-2c while the Cdc42 
(Ser30Gly-Phe56Trp) double-mutant showed a partial ability to recognize DHR-2c. 
Thus far, I have not found any other residue that contributes to the specific recognition 
of DHR-2c. Taken together, I conclude that the • 3 and switch II region of Rho 
GTPases are the critical areas for the binding of both Dock180-family and Dbl-family 
GEFs. The switch I region in the GTPases also plays an important role in the specific 
binding of both Dock180 and Dbl-family GEFs but significantly, the residues which 
make up the contact residues are different for these two families of GEFs.    
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Future investigation 
 The results from my work on the characterization of the DHR-2c domain of 
Dock180 suggest two future areas for investigation. Although it is now clear that the 
DHR-2c domain of Dock180 can activate Rac both in vitro and in vivo at high 
efficiency, it is not entirely understood how this GEF domain works on Rac. While the 
x-ray structure of the Zizimin1-Cdc42 complex is already available, because of the 
low primary sequence similarity between Zizimin1 and Dock180, it is very hard to 
predict the detailed mechanism of the Dock180-mediated Rac activation. An exciting 
but difficult challenge that remains is the determination of an x-ray crystal structure of 
the DHR-2 or the DHR-2c domain. I have already put a great deal of effort intp 
crystallization trials (see appendix) and made some improvements. However, a 
diffractable crystal has still not been obtained. The next step will be to try and 
generate new constructs of the DHR-2c domain based on secondary structural 
predictions and the x-ray crystal structure of the Zizimin-Cdc42 complex. Attempts 
should be make toward moving the flexible region of the C-terminal of DHR-2c or 
adding a helical region at the N-terminus to match the Zizimin1PDHR-2P construct.  
 Future efforts should also be invested in additional mutagenesis work on both 
DHR-2c and Rac. I have already shown that Met1524 of Dock180 specifically 
interacts with Trp56 of Rac. There is another important residue, Asn1527 in DHR-2c, 
which also makes hydrogen bonding constant with Trp56 of Rac. This residue is also 
divergent between Dock180 and Zizimin1 (i.e. the latter has a glutamine residue at the 
same position). It would be of interest to mutate this residue and check to see whether 
it also contributes to Rac-specific recognition. In addition, there are several residues 
within Dock180 which are in close distance to Ala27 of Rac, another critical residue 
that helps Rac to couple to DHR-2c. Finally, in the future it would be interesting to 
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prepare recombinant Zizimin1 and determine whether these residues that have been to 
be important for the Dock180-mediated activation of Rac play corresponding roles in 
the ability of Zizimin1 to activate Cdc42. Collectively, the results of these experiments 
would  go a long way toward providing a comprehensive picture of how Dock180-
family GEFs activate their target GTPases.  
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APPENDIX 
Purification of DHR-2c and the DHR-2c-Rac complex 
 Since x-ray the structure for the complex between Tiam1 and Rac was solved 
in 1998 (1), a number of structures of Dbl-GEFs and their complexes with Rho 
GTPases have been determined either by x-ray crystallography or NMR spectroscopy 
(2). Based on this molecular information, a good deal of work has been done to 
investigate the detailed catalytic mechanism of Dbl-GEFs. Only recently has structural 
information become available for a Dock180-family member based on the reported x-
ray structure of DHR-2 (Dock9) bound to Cdc42 (3). However, because of the low 
similarity between Zizimin1 and Dock180, and given that many experimental results 
obtained for the Dock180-catalyzed activation of Rac can not be explained by 
analyzing the structure of the Zizimin1-Cdc42 complex, it is still of great interest to 
obtain structural information for a Dock180-Rac complex. Full-length Dock180 is 
approximately 180 kDa and is difficult to express in bacteria. Likewise the DHR-2 
domain (amino acids 1111 to 1657) is difficult and a slightly shorter version of the 
DHR-2 domain (amino acids 1178 to 1657) is not stable in low salt solution and tends 
to aggregate. Thus, we are putting significant effort into the newly delineated DHR-2c 
sub-domain. This functional sub-domain can be  expressed in E.coli and is stable in 
low salt solution. If we can purify the DHR-2c sub-domain or the complex of DHR-2c 
and Rac, it should be possible to crystallize the proteins and solve their structures. 
 DHR-2c is stable in solution with 100 mM NaCl. However, after purification, 
the DHR-2c preparation appeared as a doublet on SDS PAGE (Appendix-1). The two 
bands were confirmed to be DHR-2c by Western blot analysis and further purification 
did not resolve the two bands. After I excluded the possibility of degradation, I   
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Appendix-1 DHR-2c is a doublet on SDS-PAGE (7%-15% gradient gel). This is 
likely due to the partial degradation of the His-Tag. Thrombin treatment removed the 
His-Tag and yield a single protein band.  
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suspected that the doublet was due to the partial degradation of the His-tag. To 
confirm this, I treated DHR-2c with thrombin, following the nickel affinity column, at 
4°C overnight. SDS PAGE showed that DHR-2c was uniform and appeared as a band 
(Appendix-1). A final gel-filtration step yielded a preparation of DHR-2c that was 
greater than 95% pure.  
 The purification of Rac was straight-forward. The critical element in the 
purification is Mg2+, which is needed throughout the entire purification process. 
Without MgCl2, Rac can not bind GDP with high affinity and degrades easily. In order 
to form a stable complex, DHR-2c and Rac were mixed in a molar ratio 1:2 in buffer 
with EDTA (see Chapter 2 “Methods”). A G75-sizing column was used to separate the 
Rac-DHR-2c compelx from free Rac protein (Appendix-2).  
 
Crystallization of DHR-2c and the DHR-2c-Rac complex 
 Our ultimate aim is to crystallize DHR-2c, alone, and bound to Rac. I have 
made some progress on these efforts which are still ongoing. When I set up 
crystallization screens for DHR-2c, I found out that it was easy to precipitate at 
relatively low concentrations (3-5 mg/ml). Although DHR-2c is much more stable 
than DHR-2, soluble DHR-2c still exhibited a monomeric state and an aggregation 
state during purification process as shown in Figure 2.11.  Although I collected the 
proteins in the monomeric state, I suspected that a portion of the proteins aggregated 
when their concentration was increased. This may prevent DHR-2c from crystallizing.  
 The complex between DHR-2c and Rac appears to be reasonably stable 
(Appendix-2). As mentioned above, DHR-2c prevents Rac from undergoing 
degradation. There is a possibility that Rac also prevents DHR-2c from self-   
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Appendix-2 Isolation of a complex between DHR-2c and Rac. DHR-2c and Rac 
were mixed at a 2:1 molar ration and applied to a Superdex G75 gel-filtration 
column. The first protein peak represents a complex of DHR-2 and Rac, while the 
second peak represents excess (free) Rac.  
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aggregation because the complex between Rac and DHR-2c can be concentrated to a 
maximum concentration of 100 mg/ml. Macro Screen 1-2, Index Screen 1-2, and all 
other screening conditions from the Hampton Research Kit were used to screen for the 
proper crystallization condition for the complex. Thus far, I found some conditions 
which gave micro-crystals of the complex. However, well-organized or diffractable 
crystals have not yet been obtained. Additional screens are still in process to obtain 
good-quality crystals. I am also trying to add some reagents (glycerol, NDSB-201) 
which will prevent protein aggregation and were used for the crystallization of the 
Dock9-Cdc42 complex. Modification of the DHR-2c domain, such as adding more 
residues at the N-terminus, is also under consideration.  
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